

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/6257225>

The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy...

Article in Health technology assessment (Winchester, England) · August 2007

DOI: 10.3310/hta11240 · Source: PubMed

CITATIONS

48

READS

355

14 authors, including:



Graham Pluck

Universidad San Francisco de Quito (USFQ)

43 PUBLICATIONS 946 CITATIONS

[SEE PROFILE](#)



Denzil Edwards

7 PUBLICATIONS 280 CITATIONS

[SEE PROFILE](#)



Richard Brown

King's College London

228 PUBLICATIONS 18,604 CITATIONS

[SEE PROFILE](#)



Renee Romeo

King's College London

69 PUBLICATIONS 1,637 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



PROMS-PD [View project](#)



Combining non-invasive brain stimulation and robot therapy for the impaired upper limb in stroke
[View project](#)


The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis

DM McLoughlin, A Mogg, S Eranti, G Pluck, R Purvis, D Edwards, S Landau, R Brown, S Rabe-Heskith, R Howard, M Philpot, J Rothwell, R Romeo and M Knapp



July 2007

Health Technology Assessment
NHS R&D HTA Programme
www.hta.ac.uk





INAHTA

How to obtain copies of this and other HTA Programme reports.

An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (<http://www.hta.ac.uk>). A fully searchable CD-ROM is also available (see below).

Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public **and** private sector purchasers from our Despatch Agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.

You can order HTA monographs from our Despatch Agents:

- fax (with **credit card** or **official purchase order**)
- post (with **credit card** or **official purchase order** or **cheque**)
- phone during office hours (**credit card** only).

Additionally the HTA website allows you **either** to pay securely by credit card **or** to print out your order and then post or fax it.

Contact details are as follows:

HTA Despatch
c/o Direct Mail Works Ltd
4 Oakwood Business Centre
Downley, HAVANT PO9 2NP, UK

Email: orders@hta.ac.uk
Tel: 02392 492 000
Fax: 02392 478 555
Fax from outside the UK: +44 2392 478 555

NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume.

Payment methods

Paying by cheque

If you pay by cheque, the cheque must be in **pounds sterling**, made payable to *Direct Mail Works Ltd* and drawn on a bank with a UK address.

Paying by credit card

The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.

Paying by official purchase order

You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK.

How do I get a copy of HTA on CD?

Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. *HTA on CD* is currently free of charge worldwide.

The website also provides information about the HTA Programme and lists the membership of the various committees.

The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis

DM McLoughlin,^{1*} A Mogg,¹ S Eranti,¹ G Pluck,¹
R Purvis,¹ D Edwards,² S Landau,³ R Brown,⁴
S Rabe-Heskith,³ R Howard,¹ M Philpot,⁵
J Rothwell,⁶ R Romeo⁷ and M Knapp⁷

¹ Section of Old Age Psychiatry, Institute of Psychiatry, London, UK

² Pembury Hospital, Tunbridge Wells, Kent, UK

³ Department of Biostatistics and Computing, Institute of Psychiatry, London, UK

⁴ Department of Psychology, Institute of Psychiatry, London, UK

⁵ Maudsley Hospital, London, UK

⁶ Institute of Neurology, London, UK

⁷ Centre for Economics of Mental Health, Institute of Psychiatry, London, UK

* Corresponding author

Declared competing interests of authors: none

Published July 2007

This report should be referenced as follows:

McLoughlin DM, Mogg A, Eranti S, Pluck G, Purvis R, Edwards D, *et al*. The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. *Health Technol Assess* 2007; **11**(24).

Health Technology Assessment is indexed and abstracted in *Index Medicus/MEDLINE*, *Excerpta Medica/EMBASE* and *Science Citation Index Expanded (SciSearch®)* and *Current Contents®/Clinical Medicine*.

NIHR Health Technology Assessment Programme

The Health Technology Assessment (HTA) programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.

The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'.

The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA Programme then commissions the research by competitive tender.

Secondly, the HTA Programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Thirdly, through its Technology Assessment Report (TAR) call-off contract, the HTA Programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer-reviewed by a number of independent expert referees before publication in the widely read monograph series *Health Technology Assessment*.

Criteria for inclusion in the HTA monograph series

Reports are published in the HTA monograph series if (1) they have resulted from work for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this monograph was commissioned by the HTA Programme as project number 98/11/04. The contractual start date was in August 2001. The draft report began editorial review in September 2005 and was accepted for publication in February 2007. As the funder, by devising a commissioning brief, the HTA Programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme or the Department of Health.

Editor-in-Chief:

Professor Tom Walley

Series Editors:

Dr Aileen Clarke, Dr Peter Davidson, Dr Chris Hyde,
Dr John Powell, Dr Rob Riemsma and Dr Ken Stein

Managing Editors:

Sally Bailey and Sarah Llewellyn Lloyd

ISSN 1366-5278

© Queen's Printer and Controller of HMSO 2007

This monograph may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising.

Applications for commercial reproduction should be addressed to: NCCHTA, Mailpoint 728, Boldrewood, University of Southampton, Southampton, SO16 7PX, UK.

Published by Gray Publishing, Tunbridge Wells, Kent, on behalf of NCCHTA.

Printed on acid-free paper in the UK by St Edmundsbury Press Ltd, Bury St Edmunds, Suffolk.



Abstract

The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis

DM McLoughlin,^{1*} A Mogg,¹ S Eranti,¹ G Pluck,¹ R Purvis,¹ D Edwards,² S Landau,³ R Brown,⁴ S Rabe-Heskith,³ R Howard,¹ M Philpot,⁵ J Rothwell,⁶ R Romeo⁷ and M Knapp⁷

¹ Section of Old Age Psychiatry, Institute of Psychiatry, London, UK

² Pembury Hospital, Tunbridge Wells, Kent, UK

³ Department of Biostatistics and Computing, Institute of Psychiatry, London, UK

⁴ Department of Psychology, Institute of Psychiatry, London, UK

⁵ Maudsley Hospital, London, UK

⁶ Institute of Neurology, London, UK

⁷ Centre for Economics of Mental Health, Institute of Psychiatry, London, UK

* Corresponding author

Objective: To investigate if repetitive transcranial magnetic stimulation (rTMS) was as effective as electroconvulsive therapy (ECT) in treating major depressive episodes and to perform a cost-effectiveness analysis.

Design: A single-blind pragmatic multicentre randomised controlled trial (RCT) with 6 months of follow-up to test equivalence of rTMS with ECT.

Setting: The South London and Maudsley NHS Trust and Pembury Hospital in the Invicta Mental Health Trust in Kent.

Participants: Right-handed adult patients referred for ECT for treatment of a major depressive episode (DSM-IV) were assessed. During the 2.5-year trial period, 260 patients were referred for ECT, of whom 46 entered the trial. The main reason for not entering the trial was not consenting to ECT while being formally treated under the UK Mental Health Act 1983.

Interventions: Patients were randomised to receive a 15-day course of rTMS of the left dorsolateral prefrontal cortex ($n = 24$) or a course of ECT ($n = 22$).

Main outcome measures: Patients were assessed before randomisation, at end of treatment and at the 6-month follow-up. Primary outcome measures were the 17-item Hamilton Rating Scale for Depression (HRSD) and proportion of remitters (defined as HRSD score ≤ 8) at the end-of-treatment time point.

Secondary outcomes included self-ratings for mood on the Beck Depression Inventory-II (BDI-II) and visual analogue mood scales (VAMS), the Brief Psychiatric Rating Scale (BPRS), plus subjective and objective side-effects. Low scores on the BDI-II, VAMS and BPRS are positive in terms of health. The results were analysed on an intention-to-treat basis. Cost data were collected using the Client Service Receipt Inventory and the Short Form with 36 Items was used to obtain quality of life measures. Health economic outcomes were cost of treatments, costs incurred during the 6-month follow-up period and gains in quality-adjusted life-years (QALYs).

Results: One patient was lost to follow-up at end of treatment and another eight at 6 months. The end-of-treatment HRSD scores were lower for ECT, with 13 (59%) achieving remission compared with four (17%) in the rTMS group. However, HRSD scores did not differ between groups at 6 months. BDI-II, VAMS and BPRS scores were lower for ECT at end of treatment and remained lower after 6 months. Improvement in subjective reports of side-effects following ECT correlated with antidepressant response. There was no difference between the two groups before or after treatment on global measures of cognition. Although individual treatment session costs were lower for rTMS than ECT, the cost for a course of rTMS was not significantly different from that for a course of ECT as

more rTMS sessions were given per course. Service costs were not different between the groups in the subsequent 6 months but informal care costs were significantly higher for the rTMS group and contributed substantially to the total cost for this group during the 6-month follow-up period. There also was no difference in gain in QALYs for ECT and rTMS patients. Analysis of cost-effectiveness acceptability curves demonstrated that rTMS has very low probability of being more cost-effective than ECT.

Conclusions: ECT is a more effective and potentially cost-effective antidepressant treatment than 3 weeks

of rTMS as administered in this study. Optimal treatment parameters for rTMS need to be established for treating depression. More research is required to refine further the administration of ECT in order to reduce associated cognitive side-effects while maintaining its effectiveness. There is a need for large-scale, adequately powered RCTs comparing different forms of ECT. The next generation of randomised trials of rTMS should also seek to compare treatment variables such as stimulus intensity, number of stimuli administered and duration of treatment, with a view to quantifying an effect size for antidepressant action.



Contents

List of abbreviations	vii	4 Results	13
Executive summary	ix	Participant flow and follow-up	13
1 Objective of the study	1	Response to treatment	13
2 Introduction	3	Subjective and objective side-effects	16
Depression and ECT	3	Economic analyses	16
Acceptability of ECT	3	5 Discussion	23
Cognitive dysfunction, depression and ECT	3	The antidepressant effects of ECT and rTMS	23
Repetitive transcranial magnetic stimulation: how it works	3	Side-effects	24
Transcranial magnetic stimulation: safety issues	4	Economic evaluations	24
rTMS and depression	4	6 Conclusions	27
Comparisons between ECT and rTMS for treating depression	5	Implications for the NHS	27
Quality of life and costs of ECT and rTMS	5	Recommendations for further research	27
3 Methods	7	Acknowledgements	29
Design	7	References	31
Trial participants	7	Health Technology Assessment reports published to date	37
Interventions	7	Health Technology Assessment Programme	51
Outcomes	8		
Sample size and statistical methods	9		
Economic evaluations	10		



List of abbreviations

AMI	Autobiographical Memory Interview	HRSD	Hamilton Rating Scale for Depression
ANCOVA	analysis of covariance	ICER	incremental cost-effectiveness ratio
APB	abductor pollicis brevis	MDD	major depressive disorder
BDI	Beck Depression Inventory	MMSE	Mini Mental State Examination
BPRS	Brief Psychiatric Rating Scale	MT	motor threshold
CAMCOG	Cambridge Cognitive Examination	NICE	National Institute for Health and Clinical Excellence
CEAC	cost-effectiveness acceptability curve	QALY	quality-adjusted life-year
CI	confidence interval	rTMS	repetitive transcranial magnetic stimulation
CSRI	Client Service Receipt Inventory	SCID	Structured Clinical Interview for DSM-IV Axis I Disorders
CSSSES	Columbia ECT Subjective Side Effects Schedule	SD	standard deviation
<i>df</i>	degrees of freedom	SF-36	Short Form with 36 Items
DLPFC	dorsolateral prefrontal cortex	ST	seizure threshold
ECT	electroconvulsive therapy	VAMS	visual analogue mood scales
EEG	electroencephalogram		
HRQoL	health-related quality of life		

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices in which case the abbreviation is defined in the figure legend or at the end of the table.



Executive summary

Background

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that can be used to target neuronal circuitry implicated in neuropsychiatric disorders, such as the dorsolateral prefrontal cortex (DLPFC) in depression. rTMS has been reported to be as effective as electroconvulsive therapy (ECT), which is currently the most powerful treatment available for severe depression.

Objective

The aim of this study was to investigate if rTMS was as effective as ECT in treating major depressive episodes and to perform a cost-effectiveness analysis.

Methods

Design

The study was a single-blind pragmatic multicentre randomised controlled trial (RCT) with 6 months of follow-up to test equivalence of rTMS with ECT.

Setting

The study took place in the South London and Maudsley NHS Trust and Pembury Hospital in the Invicta Mental Health Trust in Kent.

Participants

Right-handed adult patients referred for ECT for treatment of a major depressive episode (DSM-IV) were assessed. During the 2.5-year trial period, 260 patients were referred for ECT, of whom 46 entered the trial. The main reason for not entering the trial was not consenting to ECT while being formally treated under the UK Mental Health Act 1983.

Interventions

Patients were randomised to receive a 15-day course of rTMS of the left DLPFC ($n = 24$; 20 trains per day, 5 seconds of treatment at 10 Hz, 110% of motor threshold) or a course of ECT

($n = 22$; stimulus dosing method, 1.5 times the seizure threshold, course length decided by referring physician).

Main outcome measures

Patients were assessed before randomisation, at end of treatment and at the 6-month follow-up. Primary outcome measures were the 17-item Hamilton Rating Scale for Depression (HRSD) and proportion of remitters (defined as HRSD score ≤ 8) at the end-of-treatment time point. Secondary outcomes included self-ratings for mood on the Beck Depression Inventory-II (BDI-II) and visual analogue mood scales (VAMS), the Brief Psychiatric Rating Scale (BPRS), plus subjective and objective side-effects. Low scores on the BDI-II, VAMS and BPRS are positive in terms of health. The results were analysed on an intention-to-treat basis. Cost data were collected using the Client Service Receipt Inventory and the Short Form with 36 Items (SF-36) was used to obtain quality of life measures. Health economic outcomes were cost of treatments, costs incurred during the 6-month follow-up period and gains in quality-adjusted life-years (QALYs).

Data analysis

HRSD and other clinical outcome scores were compared between groups using an analysis of covariance (ANCOVA) model with baseline scores as covariates. Trial data that became available before recruitment began allowed revision of samples sizes such that 22 subjects per treatment group would be sufficient to have 80% power to demonstrate, using a one-sided equivalence test at the $\alpha = 0.5$ level, that the mean reduction in HDRS score using rTMS would be no more than 25% less than that achieved using ECT.

Results

One patient was lost to follow-up at end of treatment and another eight at 6 months. The end-of-treatment HRSD scores were lower for ECT [95% confidence interval (CI) 3.40 to 14.05, $p = 0.002$], with 13 (59%) achieving remission compared with four (17%) in the rTMS group ($p = 0.005$). However, HRSD scores did not differ

between groups at 6 months. BDI-II, VAMS and BPRS scores were lower for ECT at end of treatment and remained lower after 6 months. Improvement in subjective reports of side-effects following ECT correlated with antidepressant response. There was no difference between the two groups before or after treatment on global measures of cognition.

Although individual treatment session costs were lower for rTMS than ECT, the cost for a course of rTMS was not significantly different from that for a course of ECT as more rTMS sessions were given per course. Service costs were not different between the groups in the subsequent 6 months but informal care costs were significantly higher for the rTMS group ($p = 0.04$) and contributed substantially to the total cost for this group during the 6-month follow-up period. There was also no difference in gain in QALYs for ECT and rTMS patients. Analysis of cost-effectiveness acceptability curves demonstrated that rTMS has very low probability of being more cost-effective than ECT.

Limitations

Rater blinding was not maintained and is a potential source of bias. However, similar results

were obtained on both observer- and self-rated measures. The optimal parameters for administering rTMS to achieve an antidepressant effect are not yet known.

Conclusions

ECT is a more effective and potentially cost-effective antidepressant treatment than 3 weeks of rTMS as administered in this study. Optimal treatment parameters for rTMS need to be established for treating depression. More research is required to refine further the administration of ECT in order to reduce associated cognitive side-effects while maintaining its effectiveness.

Recommendations for further research

There is a need for large-scale, adequately powered RCTs comparing different forms of ECT. The next generation of randomised trials of rTMS should also seek to compare treatment variables such as stimulus intensity, number of stimuli administered and duration of treatment, with a view to quantifying an effect size for antidepressant action.

Chapter I

Objective of the study

The objective of this study was to carry out a pragmatic randomised controlled trial of repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) for treating major depressive episodes in patients

referred for ECT, including a cost-effectiveness analysis. A pragmatic design was chosen so that the trial would resemble and reflect routine practice as much as possible such that the results would be generalisable throughout the NHS.

Chapter 2

Introduction

Depression and ECT

Major depressive disorder (MDD)¹ is one of the leading causes of the global burden of disease,² with 13% of men and 21% of women affected at some point in their lives. Treating depression in England and Wales costs £420 million per year and indirect costs exceed £3 billion.³ These figures can only be rough estimates but are probably of the correct order of magnitude. Major depression has a high relapse rate and recurring episodes are associated with increasing risk of chronicity coupled with long-term psychosocial impairment and distress, loss of productivity, disruption of normal social relationships and suicide.⁴

It is important, therefore, that all severe episodes be treated early and vigorously to reduce disability and prevent morbidity.⁵ However, up to 30% of patients with severe depression fail to respond sufficiently to trials of antidepressant medications given at adequate doses for at least 6 weeks.^{6,7} Frequently these patients (and also severely ill patients and those unable to tolerate antidepressant medication) are treated with ECT. Even though 'medication resistance' is associated with a poorer response to ECT, at least 50% of the 'resistant' group will respond; in fact, response rates to ECT may be even higher, up to 85%, in patients who have not failed a medication trial.⁸

Acceptability of ECT

A recent meta-analysis has confirmed that ECT is one of the most effective treatments available for severe depression⁹ and this indication has been approved in the UK by the National Institute for Health and Clinical Excellence (NICE).¹⁰ However, it is rarely a first- or even second-line treatment and is generally reserved for either very ill patients or patients refractory to standard treatments. The reasons for this are not clear but are most likely to be due to issues of acceptability of ECT related to repeated general anaesthesia, application of an electric charge through the brain, induction of a seizure and cognitive side-effects. Interestingly, patients treated with ECT have been reported to develop a more positive

attitude towards it, as do their relatives.¹¹⁻¹⁴ Nonetheless, there still remains the important issue of adverse cognitive side-effects of ECT.

Cognitive dysfunction, depression and ECT

In severe depression, there is a consistent picture of impaired memory function and frontal-executive deficits.^{15,16} Such changes are consistent with the predominantly prefrontal patterns of cerebral blood-flow abnormalities observed in neuroimaging studies.^{17,18} Depression-related cognitive impairment typically improves on remission of the mood disturbance, a change associated with normalisation of frontal metabolic function.¹⁸ Cognitive changes due to depression can be distinguished from those due to ECT. The immediate adverse cognitive side-effects of ECT result mainly from the anaesthesia and seizure. Headache, disorientation and memory complaints are the most common subjective side-effects.¹⁹ Both subjective complaints¹⁹ and objective measures of cognitive impairment²⁰ can worsen during treatment, despite improvements in subjective mood. Significant improvements in cognitive function after 6 months²¹ and even 4 years²² following ECT have been reported.

However, more recently there has been growing concern that ECT may cause longer lasting cognitive impairment that is not related to enduring depression.²³ In particular, ECT has been reported to cause retrograde amnesia and this is more problematic with bilateral than unilateral ECT, even high-dose unilateral ECT.^{24,25} There is clearly a need to develop ECT further to reduce its side-effects while simultaneously maintaining its efficacy. Alternatively, another treatment as effective as ECT but without its side-effects or problems with acceptability would be welcomed by both patients and physicians.

Repetitive transcranial magnetic stimulation: how it works

One potential alternative to ECT might be rTMS.^{26,27} TMS works by passing an electric

current through a hand-held coil and using this to focus an electromagnetic field, that is changing over time, on to the scalp.²⁸ The magnetic field rapidly falls off 1–2 cm from the surface of the cortex. Following Faraday's law, this induces eddy currents (proportional to the rate of change of the magnetic field) in the underlying cerebral cortex, thereby stimulating neural tissue, probably by depolarisation. In ECT, high voltages are required to enable an electrical stimulus to pass through the strongly insulating scalp and skull, whereas pulsed magnetic fields readily pass through unattenuated to produce electrical effects in the cortex. Hence TMS, as opposed to ECT, can induce cortical electrical activity without causing a seizure, that is, it is sub-convulsive, and does not require any anaesthesia.

TMS technology was initially developed to map cortical function and investigate the integrity of corticospinal pathways by stimulating the motor cortex and observing peripheral muscle activity and motor evoked potentials.^{29,30} Contemporary machines can produce large, rapidly changing magnetic forces and are capable of precisely delivering repetitive pulses of up to 50 stimuli per second to targeted cortical regions. Depending on the settings used, small induced currents can then make brain areas below the coil more or less active. For example, rapid (i.e. 1–20 Hz) rTMS is activating whereas slow (i.e. <1 Hz) rTMS is inhibitory.³¹ Single-pulse TMS and rTMS have been demonstrated to affect many brain functions temporarily, including movement, visual perception, memory, reaction time, speech and mood, and have been widely used to investigate brain function.^{26,27,32,33}

Transcranial magnetic stimulation: safety issues

TMS is considered to be a safe tool for neurological investigation and in limited studies has not been reported to cause any changes to cerebral structures on either histological examination or neuroimaging.^{34,35} Nor is there any evidence of immediate cognitive side-effects such as occur with ECT,^{36–38} although few data are available on possible long-term cognitive sequelae. There is a risk of inducing seizures with rTMS due to repetitive cortical activation (see Chapter 3 for a detailed discussion of the administration and safety of rTMS). Most of this increased risk has been attributed to giving stimuli too frequently, at too high an intensity, and without sufficient time gaps between trains of stimuli.³⁹ Clinical and

research experience with rTMS has informed safety guidelines for treatment parameters.^{40–42}

rTMS and depression

Early trials of rTMS, mostly uncontrolled and open with small numbers, indicated that it might be beneficial in up to 50% of patients with treatment resistant depression.^{43–46} The studies also helped to refine some of the safety aspects and the parameters required for therapeutic application of rTMS. These include the efficacy and safety of sub- and moderately supra-motor threshold (MT) stimulus intensities (90–110%), the optimal frequency of fast stimuli (10–20 Hz), the duration of treatment sessions and number of sessions required (at least five), and also the identification of the left dorsolateral prefrontal cortex (DLPFC) as possibly the best treatment site. A theoretical mechanism for this lateralised effect on mood may relate to the evidence cited above that focal reductions in glucose metabolism and blood flow in the left DLPFC are associated with major depression and that these abnormalities normalise with treatment and recovery.

The first double-blind, randomised, placebo-controlled study with a multiple cross-over design was carried out by Pascual-Leone and colleagues (1996)⁴⁷ on 17 patients with medication-resistant psychotic depression. Their aim was to study the effect of sub-threshold (90%) stimulation at 10 Hz of the left DLPFC. Each patient received five treatment courses in randomised order for 5 days at the beginning of each month over 5 months: real and sham left DLPFC, real and sham right DLPFC and real vertex stimulation. Each session comprised 2000 stimuli daily (20 trains of 10-s duration separated by 60-s intervals). Only left DLPFC rTMS resulted in a statistically significant decrease in Hamilton Rating Scale for Depression (HRSD) scores (from a mean of 25.2 to 13.8) and after 5 days 11 of 17 patients showed improvement, which then diminished over the next 2 weeks. This study is unusual in the high degree of cooperation and compliance that the researchers obtained from such severely ill patients.

Nevertheless, many subsequent studies found similar results. For example, George and colleagues⁴⁸ examined the effect of daily left DLPFC rTMS (80% of MT, 20 Hz, 20 trains of 2 s each, 60 s apart, i.e. 800 pulses per session) on 12 patients with major depressive episodes. They used a placebo-controlled, cross-over design and found statistically significant reductions in HDRS

scores (mean reduction 5.25) after two weeks (ten sessions) of rTMS treatment. In another open trial, Figiel and colleagues⁴⁹ treated 50 patients with treatment refractory depression with rTMS to the left DLPFC for five consecutive weekdays (110% of MT, 10 Hz, 10 trains of 5 s each, 30 s apart). There were 21 (42%) responders who had a 60% reduction in their pretreatment HRSD scores. Interestingly, 57% (16/28) of patients aged under 65 years responded whereas only 23% (5/22) of patients aged over 65 years responded.

Not all early trials of rTMS in depression were positive. Loo and colleagues⁵⁰ studied 18 treatment-resistant patients with DSM-IV major depression who were randomly allocated to 2 weeks (10 consecutive weekdays) of real or sham rTMS (110% of MT, 10 Hz, 30 trains of 5 s each, 30 s apart) while continuing to take antidepressant medication. During the 2-week study period, both groups improved equally well with a reduction in HRSD scores similar to that reported in George and colleagues' study.⁴⁸ The researchers expressed some surprise at their finding, considering the refractory nature of the depression being treated, but could not identify any factors for this beyond increased clinical contact and the possibility of the repetitive sham treatments actually delivering a therapeutic stimulus.

Other studies have investigated using slow rTMS to **inhibit** the **right** DLPFC to rectify any possible imbalance in prefrontal activities in depression. A controlled double-blind study of rTMS in 70 patients with DSM-IV major depression reported that nearly 50% of the real rTMS group, compared with 25% of the sham group, decreased their HDRS scores by more than 50% from pretreatment levels.⁵¹ rTMS was delivered over 2 weeks to the **right** DLPFC at **low** frequency (1 Hz) and 110% of MT. Two trains of 60 stimuli were delivered for 1 minute each with a 3-minute interval. This was the first substantial trial of using low-frequency right-sided rTMS and revealed that the definitive treatment parameters for rTMS in depression remained to be finalised (and they still do), and that there is probably a range of potentially effective parameter sets. Furthermore, it is not yet clear what patient characteristics will best predict a response to rTMS or what the long-term consequences of rTMS are with regard to maintenance of antidepressant effect, relapse rate and side-effects.

Several meta-analyses of controlled trials (ranging from five to 14 trials) of rTMS in depression have been published since the present study began.⁵²⁻⁵⁷

In general, these have highlighted the large degree of heterogeneity that exists between studies and the variable, often low, standard of published trials. Indeed, because of this, one group of researchers felt that a formal meta-analysis was not possible.⁵⁸ For example, both crossover and parallel group studies are often included together, whereas it is usually obvious to the trial subject that there is a difference between the experience of real and sham rTMS and thus blinding is lost. The meta-analyses are further compromised by the use of different types of 'sham' rTMS. For example, many studies have delivered sham rTMS by angling the coil away from the scalp rather than using purpose-built sham coils. However, it appears that this type of 'sham' treatment can actually have a 'real' effect as the magnetic field can still penetrate through to the underlying cortex.^{59,60} While the earlier meta-analyses^{52,53} are cautiously supportive of a therapeutic role for rTMS in depression and discuss the need for more and better trials, the more recent meta-analyses^{56,57} are less supportive.

What is clear from the meta-analyses, however, is that in order to develop rTMS as a treatment for depression, further research is required to optimise treatment parameters (e.g. stimulus site, intensity and frequency of stimuli, duration of treatment).

Comparisons between ECT and rTMS for treating depression

During the course of the present study, several randomised trials comparing up to 4 weeks of rTMS with ECT for treating depression have been published. Initial randomised studies suggested that effectiveness may approach that of ECT, particularly in non-delusional depression.⁶¹⁻⁶⁴ Relapse rates over 6 months in responders to rTMS or ECT in randomised studies have been reported to be similar at about 20% for both treatments.⁶⁵

Quality of life and costs of ECT and rTMS

To facilitate formulating policies about the use of resources, it is important to translate the burden of illness and cost of treatment into economic values. Therefore, when a new treatment for affective disorders becomes available that is a potential alternative to an established treatment, as rTMS is for ECT, it is essential not only to

demonstrate the new treatment's effectiveness but also to establish its cost and compare this with the established treatment in a cost-effectiveness analysis.

ECT has been reported to be associated with improved quality of life that is evident within the first month post-treatment and that can be maintained for up to 1 year.^{66,67} Quality of life data following treatment with rTMS are not available. There are no cost-effectiveness data currently available for ECT and a recent attempt

to generate a model proved inconclusive, mainly due to a lack of suitable randomised controlled trial data and uncertainty around the optimal treatment parameters for ECT.⁶⁸ No reports have yet been published on the costs associated with using rTMS to treat depression. However, using the USA insured population and based on the assumption that rTMS is equally effective as ECT, a decision analysis model of cost-effectiveness concluded that rTMS would cost less than ECT.⁶⁹

Chapter 3

Methods

Design

The study was a two-group parallel design pragmatic randomised controlled trial⁷⁰ of rTMS versus ECT for patients with a major depressive episode (DSM-IV¹) who had been referred for ECT. Following baseline assessment, consenting patients were randomly allocated to a course of either ECT or rTMS by an independent third party who was a member of the academic staff but otherwise had no involvement with the trial or relevant researchers. A protected and concealed computer database (Microsoft Access) containing the randomisation list was used to ensure allocation concealment. Randomisation was stratified by health trust. Subsequent ratings were performed by trained research workers blind to treatment modality.

Because of the obviously different natures of the two treatments, it was not possible for patients to be blind to their allocated treatment. Patients and their healthcare staff were asked not to discuss treatment details with the raters. To test blinding, raters were asked to guess what treatment had been allocated after the end-of-treatment assessment. Apart from the interventions under study, both groups continued to receive the standard treatment package usually prescribed by the referring NHS physician and care team.

Trial participants

Patients were recruited from six hospitals in the South London and Maudsley (SLaM) NHS Trust and Pembury Hospital in the Invicta Mental Health Trust in Kent. ECT was administered at three of the South London and Maudsley facilities (The Maudsley Hospital, Bethlem Royal Hospital and Lewisham General Hospital) two of which also provided rTMS (The Maudsley and Bethlem Royal Hospitals). Both ECT and rTMS were administered at Pembury Hospital. Recruitment was between January 2002 and August 2004. Right-handed patients aged over 18 years referred for ECT to treat a major depressive episode were invited to enter the study. Diagnosis was confirmed using the mood disorders module of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID).⁷¹

Exclusion criteria were inability to provide informed consent; unable to have rTMS due to presence of metallic implants or foreign bodies or previous history of seizures; history of substance misuse in the past 6 months; any medical condition rendering the patient unfit to have a general anaesthetic; ECT or rTMS in the previous 6 months; evidence of dementia or other Axis 1 diagnosis. The study was approved by the local ethics committees and all participants provided written informed consent.

Interventions

rTMS was given by research physicians using the Magstim Super Rapid stimulator (Magstim Co. Ltd, Whitland, UK) with a figure-of-eight coil kept cooled on ice, essentially as previously described.^{61,63} Research physicians kept social interactions with patients to a minimum. In the first session, the MT of the abductor pollicis brevis (APB) site in the left motor cortex was determined by visual inspection using a method of limits.⁷² The MT is the minimum stimulus required to activate the APB and was used to calibrate the treatment stimulus. Patients were seated in a reclined chair and wore cotton skull caps upon which target points were marked. Using single stimuli at the same intensity (e.g. 40% of output), the stimulating coil was moved over the left motor cortex in a straight line in 1-cm steps to map the activation point of the APB. At the same time, the subjects were actively contracting their hand muscles in order to lower the threshold for stimulation, thus making the stimulus more focal and also making it easier to identify twitching of the APB. Having identified the best spot for activation of the APB, subjects then relaxed and the resting MT was determined. Continuing to stimulate at the APB point, the stimulus intensity was lowered to well below threshold and then increased 2% at a time, with six stimuli at each level of intensity until twitching was apparent in three or more of the six stimuli in each group. This stimulus strength was the MT for the APB point. The point for stimulation of the DLPFC was 5 cm anterior to the APB point.

Stimulations were given at 110% of the MT to the left DLPFC deemed to be located 5 cm anterior to

the APB point in the parasagittal plane. Each treatment session entailed 20 trains of rTMS at 10 Hz for 5 seconds with 55-second inter-train intervals. A full course of rTMS comprised 15 daily sessions (total of 15,000 magnetic pulses) administered on weekdays beginning on a Monday.

ECT was administered twice weekly with hand-held electrodes and according to Royal College of Psychiatrists' guidelines.⁷³ Methohexitone (0.75–1.0 mg/kg) was used for anaesthetic induction and suxamethonium (0.5–1.0 mg/kg) as muscle relaxant. The Thymatron DGx device (Somatics Inc., Lake Bluff, IL, USA) was used at the three SLAM sites and the Mecta SR2 device (Mecta Corp., Lake Oswego, OR, USA) was used at the Pembury Hospital site. Both devices deliver constant-current, bi-directional brief pulses. Seizure durations were measured by dual-channel EEG monitoring. Patients' seizure thresholds (STs) were established by a method of limits at the first treatment session as previously described.⁷⁴ Subsequent treatments were given at $1.5 \times ST$ for bilateral frontotemporal ECT and $2.5 \times ST$ for right unilateral ECT. The stimulus charge was titred upwards as required during the treatment course using standard stimulus dosing protocols.⁷³ The number of ECT treatments depended on the patient's response as determined by the referring physician.

Outcomes

The primary outcome measure for this study was the 17-item HRSD⁷⁵ score at the end of the allocated treatment and rate of remission (defined as HRSD ≤ 8). Secondary outcomes included subjective ratings of depression with both the Beck Depression Inventory-II (BDI-II)⁷⁶ and aggregated visual analogue mood scales (VAMS) score,⁷⁷ global measure of psychopathology on the Brief Psychiatric Rating Scale (BPRS)⁷⁸ and relapse rate after 6 months (defined as HRSD ≥ 12). The VAMS consists of seven brief visual scales for subjective ratings (sad, confused, afraid, happy, tired, angry and energetic), which descend vertically 100 mm from a 'neutral' option. The VAMS has been demonstrated to be both reliable and valid in healthy young adult and elderly controls and also to be a sensitive marker of treatment response to ECT.⁷⁷ The higher the score on all of these measures the greater is the severity of depression and related symptoms. Economic outcomes included costs and quality-adjusted life-years (QALYS) gained (see below).

Baseline data obtained by interview and review of hospital records also included age, sex, duration of current major depressive episode, previous history of depression and ECT, presence of psychotic symptoms (i.e. delusions and/or hallucinations) as detected on the SCID assessment, level of treatment resistance as measured by the number of adequate previous courses of antidepressants and augmentation strategies, and current psychotropic medications. End-of-treatment assessments were carried out 2–3 days after the final treatment in the allocated course and patients were also followed up for 6 months.

Subjective symptoms potentially attributable to either ECT or rTMS were assessed with a shortened version of the Columbia ECT Subjective Side Effects Schedule (CSSES)^{19,79} that was modified to document potential rTMS side-effects (e.g. seizure induction, scalp discomfort, hearing loss) and any other unpredictable adverse events due to either rTMS or ECT. The symptoms assessed by the CSSES can be grouped into four main categories: somatic, cognitive, mood and psychomotor agitation. The cognitive symptoms embedded within the CSSES allowed us to generate a self-rated measure for cognition by totalling the number of positive responses to the following five questions: Have you had trouble recalling people's names? Have you felt confused or disorientated? Have you had any memory problems? Have you had trouble concentrating? Have you had trouble holding in your memory new things you have learned?

Changes in cognitive function, due either to treatment side-effects or to treatment response, were recorded. Baseline global cognitive function was assessed using the Cambridge Cognitive Examination (CAMCOG) section of the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX) interview schedule,⁸⁰ from which it is also possible to generate a score for the Mini Mental State Examination (MMSE).⁸¹ It provides a total score (maximum 107) plus subscale scores for different aspects of cognition and has been used previously to study cognition in depression.⁸² Lower scores reflect poorer performance on testing.

In addition, the following battery of tests focusing on memory and frontal-executive function were also administered:

1. Measures of immediate short-term memory plus attention and working memory were obtained using the Forward and Backward Digit Spans.⁸³

2. Retrograde autobiographical memory was assessed using Sections 2 and 3 of the Autobiographical Memory Interview (AMI) to cover recent (i.e. within the past 5 years) and more remote (i.e. early adulthood) personal memories.⁸⁴
3. Motor and psychomotor speed were rated with the Trail Making Test (Part A);⁸⁵ the Symbol Digit Modalities Test,⁸⁶ a sensitive measure of psychomotor speed adapted from the Digit Symbol Subtest of the Wechsler Adult Intelligence Test;⁸³ and the Grooved Pegboard Test (Lafayette Instrument Co., Lafayette, IN, USA),⁸⁷ a test of speeded fine eye–hand coordination.
4. Frontal/executive function was further rated by the Trail Making Test (Part B).⁸⁵

Sample size and statistical methods

This trial was first proposed in 1999 following a call by the NHS Health Technology Assessment (HTA) programme for such a study. At that time no comparison data were available on rTMS and ECT for depression. Using response data from a large series of severely depressed patients treated with ECT in which the mean percentage decline in HRSD depression rating scores was 72.5 (23.7)%,⁸⁸ we initially estimated that 76 subjects would be required in each treatment group to have 80% power to demonstrate, using a one-sided equivalence test at the $\alpha = 0.5$ level, that the mean reduction in HRSD score using rTMS was no more than 13% (corresponding to 3.0 points on the 24-item HRSD⁸⁸) less than that achieved using ECT.

Shortly before this trial began, and in the early stages of recruitment, several reports were published indicating that rTMS was not better than ECT for depression but that its effectiveness might approach that of ECT.^{61–64} At the same time, recruitment to this trial was slower than expected despite multiple centres, possibly due to an ongoing reduction in referrals for ECT at both national and local levels.^{89,90} As a result, the initial sample size estimations were reviewed. It was deemed that if rTMS had at least 75% of the effectiveness of ECT in reducing depression scores, then rTMS would merit clinical interest for this difficult-to-treat population, particularly in the light of its safety and good side-effect profile. This change to the study methodology was approved by both the trial's steering committee and data monitoring and ethics committee; the NHS HTA was informed of the changes. Using the same ECT response data,⁸⁸ it was estimated that 22 subjects

per treatment group would be sufficient to have 80% power to demonstrate, using a one-sided equivalence test at the $\alpha = 0.5$ level, that the mean reduction in HRSD score using rTMS would be no more than 25% less than that achieved using ECT.

All outcomes were analysed on an intention-to-treat basis. HRSD scores were compared between the ECT and rTMS treatment arms using an analysis of covariance (ANCOVA) model. The model used HRSD scores at end of treatment and follow-up time points as dependent variables and included main effects of time (end of treatment or follow-up) and treatment plus their interaction. In addition, prerandomisation baseline HRSD scores were included as a covariate, as were NHS Trusts to adjust for centre effects. End of treatment was defined as the last treatment received within an allocated course, irrespective of the total number of treatments. Whereas rTMS courses were predetermined to have fixed durations, i.e. 15 weekdays, the ECT courses were of variable duration. Therefore, within-treatment-course ratings were not included in analyses. Standard errors that were robust against correlations within subject clusters were used to account for the two repeated measures per subject. If the treatment \times time interaction tested significant at the 5% significance level, two *post hoc* comparisons were carried out to compare the treatment arms separately at the end-of-treatment and follow-up time points (at the Bonferroni adjusted significance level of $5/2 = 2.5\%$). If the interaction term was not statistically significant, it was excluded from the model and the main effect of treatment evaluated to estimate the treatment effect. Standardised effect sizes were calculated by dividing the estimated group difference by a measure of background variability [standard deviation (SD) of baseline scores].

To assess the equivalence of rTMS and ECT for the primary outcome measure, the end-of-treatment estimate of group difference was transformed into an estimate of group difference in percentage reduction from baseline HRSD and a confidence interval (CI) was then established for this.

The secondary outcomes BDI-II, VAMS and BPRS were analysed using the same ANCOVA-type model as were the subjective side-effects and cognitive measures. Binary outcomes at a single time point (remission at end of treatment or relapse at follow-up) were compared between treatment groups using Fisher's exact tests.

Analyses of economic outcomes measures are discussed.

Economic evaluations

In order to carry out the economic evaluations, data were collected from patients on service utilisation and other dimensions relevant to the measurement of costs using a customised version of the Client Service Recipient Inventory (CSRI).⁹¹ The CSRI has been extensively used in studies of mental health care.⁹² The inventory uses information about the service user's background, and comprehensively gathers information about accommodation, and all health, social care and other services used. Through patient interview, data on service use were collected at baseline for the 3-month period prior to entering the study and for the 6-month post-treatment period at follow-up interviews. The CSRI provides a standardised way of recording service use that is also commensurate with accurate cost estimation.

From the completed CSRIs, a full list of services was drawn up to which approximations of the **long-run marginal opportunity cost** of each service were attached. For most services, nationally applicable unit costs at 2003–4 prices were employed, taken from the annual PSSRU compendium.⁹³ NHS reference costs were used to estimate the cost of inpatient and outpatient attendances. Details of the unit costs used are available from the authors. Direct costs of services in each of the treatment groups were derived by multiplying the frequency and duration of health and social care resources used during the study with the costs of each resource (unit costs).

The unit costs of ECT and rTMS treatment administration were estimated using local data on capital costs (including the treatment suite and machines used during treatment) and cost of professionals' time related to treatment. Capital costs were based on new build and land requirements for an NHS treatment room. This amount was annuitised at a rate of 3.5% over 60 years. The capital cost of equipment was annuitised at 3.5% over 10 years. The profession and grade of the staff involved in the treatment and time they spent on treatment were recorded. These staff included the psychiatrist administering the treatment, anaesthetist, nurse coordinator, operating department assistant and ward nurse. Unit costs for these staff were based on 2003–4 estimates taken from Curtis and Netten.⁹³ The cost of treatment in each of the two groups was then derived by multiplying the number of treatments during the study with the unit cost of treatment administration. Researchers kept

information on the number of treatment sessions attended by patients.

Unpaid care within or outside the home by family and other carers was costed using the average hourly rate for a local authority home care worker.⁹³

Mean costs were compared using Student's *t*-test and the robustness of the results confirmed using non-parametric bootstrapping techniques to account for any non-normality in their distribution. Data were analysed using SPSS v10 and STATA v8.0 (StataCorp, College Station, TX, USA).

A generic health-related quality of life (HRQoL) measure was employed to generate utility scores for one facet of the economic evaluation. This was not part of the original proposal and was added as a secondary measure following a monitoring visit. The Short Form with 36 Items (SF-36)⁹⁴ is one of the most commonly used measures of HRQoL and yields an eight-scale profile of physical functioning, role physical health, bodily pain, general health, vitality, social functioning, role emotional health and mental health well-being scores, in addition to psychometrically based physical and mental health summary measures. QALYs were estimated by combining the time the patient spends in each health state with predicted utility values of the health states. The patient's utility values were derived using SF-36 data.⁹⁵ The SF-36 was revised into a six-dimensional health state classification (the so-called SF-6D) and societal weights attached, taken from Brazier and colleagues' work.⁹⁵

The primary economic evaluation was conducted from the perspective of the health and personal social services. We also looked at these service costs plus the costs of informal care. A cost-effectiveness analysis was conducted comparing these comprehensively measured service costs between rTMS and ECT with, first, the difference between the treatments in change in the primary outcome measure (depressive symptoms as measured by the HRSD), and then with the difference between the treatments in QALYs gained. We also looked at cost-effectiveness with and without including the costs of informal care. In each case we planned to compute an incremental cost-effectiveness ratio (ICER) as the mean cost difference between rTMS and ECT divided by the mean difference in change in outcome.

In the event that one treatment was both more effective and more costly than the other, the

decision-maker would need to consider whether it is worth incurring the higher costs in order to achieve the improved outcomes. The standard approach now employed by health economists to reveal the nature of these trade-offs – and to represent the inherent uncertainty in any evaluation – is to plot a cost-effectiveness acceptability curve (CEAC).^{96,97} We did so for each cost–outcome combination.

The CEAC reveals to the decision-maker what the probability is of rTMS being seen as cost-effective relative to ECT given different (implicit monetary) values placed on incremental outcome improvements. In the present study, for each different value attached to a one-point improvement in the HRSD or for each QALY gained, we calculated this probability. The CEAC

also represents uncertainty in the estimation of the ICER, including in circumstances where statistical power limits significance testing⁹⁸ and also where one wants to understand the sensitivity of the results to key assumptions made in the analysis. Lack of statistical power is a common problem in economic evaluations, especially in the mental health area.⁹⁹ Moreover, in a decision-making context it could be argued to be perverse to reject an intervention with the highest probability of being cost-effective because of the limitations of conventional hypothesis testing.¹⁰⁰ Bootstrap analyses were used to draw 1000 repeat samples from the data and the CEAC generated by plotting the proportion of ICERs that were cost-effective for a range of willingness to pay values. The bootstrap approach also allows for possible skewness in the cost variable.^{101,102}

Chapter 4

Results

Participant flow and follow-up

The trial profile is shown in *Figure 1*. Of 260 patients referred for ECT, 107 were depressed patients eligible to enter the trial. The most common reason for exclusion was being formally treated in accordance with the UK Mental Health Act 1983 while not consenting to ECT. Of the eligible patients, 46 (43%) consented to enter the study. There was no statistical difference in mean age or sex ratio between eligible patients who consented to enter the trial and those who declined to participate. Five patients in the rTMS group terminated treatment early, having ≤ 10 sessions, because they felt no improvement, and one patient could not attend the fifteenth session; all but one of these agreed to end-of-treatment assessments. The rTMS treatments were well tolerated and nobody dropped out because of pain or discomfort at the stimulation site. None of the ECT patients dropped out at this stage of the trial.

In the ECT group, 18 (81.8%) had bilateral and four (18.2%) had unilateral ECT. The mean (standard deviation) number of rTMS sessions was 13.7 (2.7) and the mean number of ECT sessions was 6.3 (2.5) (range 2–10). Although the number of sessions differed between the two treatment groups, the durations (total number of days from first to last treatment) of the treatment courses were comparable [ECT, 22.4 (12.7); rTMS, 19.5 (6.3)]. Four patients in the rTMS group crossed over to have ECT after the end-of-treatment assessments but were analysed in the group to which they were randomised.

It proved impossible to keep assessors blind to treatment allocation. Rater treatment guesses were not available for eight patients. Of the remaining 38 patients, five had directly informed raters about their treatment and raters guessed allocated treatment correctly for 30 patients (92%). Patient demographic and clinical baseline information is summarised in *Table 1*. This shows that the randomisation reasonably balanced the treatment arms with respect to potential confounders.

Response to treatment

Changes in the HRSD scores over time in the two treatment arms are shown in *Figure 2*. The post-treatment group difference varied significantly with assessment time point [group \times time interaction: $t = -2.49$, degrees of freedom (df) = 45, $p = 0.017$]. *Post hoc* tests demonstrated that the end-of-treatment HRSD scores were significantly lower in the ECT group than the rTMS group ($t = 3.3$, $df = 45$, 95% CI 3.40 to 14.05, $p = 0.002$), demonstrating a strong standardised effect size of 1.44. However, at 6 months' follow-up, HRSD scores did not differ between the two groups ($t = -0.09$, $df = 45$, 95% CI -6.92 to 6.33, $p = 0.93$). At end of treatment, 13 patients (59%) in the ECT group met the remission criterion (HRSD ≤ 8) whereas only four (17%) did so in the rTMS group (Fisher's exact test, $p = 0.005$).

In addition to the intention-to-treat analysis, and as a sensitivity analysis, a *post hoc* received treatment analysis was performed. However, this did not affect the primary outcome. This analysis excluded the five patients in the rTMS group who had ≤ 10 rTMS sessions, and took into account the crossover of five rTMS patients to the ECT group before the 6-month follow-up assessment.

The mean reduction in HRSD score achieved at end of treatment from adjusted baseline score was 14.1 for ECT and 5.4 for rTMS. This translates into mean percentage reductions from baseline of 58% for ECT and 22% for rTMS. Thus the absolute difference in percentage reduction from baseline was 36% (95% CI 14 to 58%). This point estimate lies well outside the predefined equivalence range (i.e. up to 18.1 percentage points), as does almost all the respective CI with just a small fraction of the confidence range (from 14 to 18.1%) falling into the predefined equivalence range. The rTMS treatment effect was therefore statistically significantly worse than that of ECT and it was at least 14 percentage points worse.

Changes for the BDI-II, VAMS and BPRS scores are shown in *Figure 3*. Although these showed




FIGURE 1 Trial profile


similar patterns to the HRSD scores, there was no statistical evidence for any of these secondary outcomes that the treatment effect varied over time (group \times time interaction: BDI-II, $t = -1.2$, $df = 45$, $p = 0.25$; VAMS, $t = -1.3$, $df = 41$, $p = 0.20$; BPRS, $t = -0.85$, $df = 43$, $p = 0.40$). The interaction terms were therefore excluded

from the model and the main effect of treatment arm evaluated across the end-of-treatment and 6-month follow-up time points. This showed significantly lower scores in the ECT group compared with rTMS on the BDI-II ($t = 2.7$, $df = 45$, 95% CI 2.3 to 15.6, $p = 0.01$), VAMS ($t = 4.2$, $df = 41$, 95% CI 106.5 to 302.8,

TABLE 1 Baseline characteristics

	rTMS group ^a (n = 24)	ECT group ^a (n = 22)
Age (years)	63.6 (17.3)	68.3 (13.4)
Female	16 (67.7%)	16 (72.7%)
Inpatient	15 (62.5%)	15 (68.2%)
Patients with bipolar depression	2 (8.3%)	2 (9.1%)
Level of treatment resistance	2.4 (1.0)	2.5 (1.4)
Median duration (months) of depressive episode (range)	7.7 (0.6–24.0)	6.1 (1.4–24.0)
Number of previous depressive episodes	3.7 (2.3)	4.2 (2.6)
Previous history of ECT	15 (62.5%)	12 (54.5%)
Number of psychotropic medications per patient	1.7 (1.2)	1.7 (1.2)
Number of patients on psychotropic medications:		
SSRI	6 (25%)	5 (22.7%)
TCA	2 (8.3%)	2 (9.1%)
Venlafaxine	10 (41.7%)	7 (31.8%)
Mirtazapine	4 (16.7%)	5 (22.7%)
Lithium	5 (20.8%)	6 (27.3%)
Anticonvulsant	2 (8.3%)	3 (13.6%)
Benzodiazepines	2 (8.3%)	5 (22.7%)
Antipsychotics	7 (29.2%)	7 (31.8%)
Zopiclone	6 (25%)	3 (13.6%)
L-Tryptophan	1 (4.2%)	0 (0%)
Patients with psychosis	4 (16.7%)	3 (13.6%)
HRSD score	23.9 (7.0)	24.8 (5.0)
BDI-II score	36 (8.7)	37.8 (10.5)
VAMS aggregate score	489.0 (119.8)	572.1 (94.9)
BPRS score	36.8 (8.2)	36.4 (8.3)
SF-36 mental health component score	48.9 (12.6)	42.7 (7.5)

SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.
^a Data are mean (SD) or number (%) of patients, unless indicated otherwise.

**FIGURE 2** Mean HRSD score. The graph shows predicted mean scores per treatment arm and post-treatment time points, adjusted to sample average baseline values, with 95% CIs.




FIGURE 3 Mean BDI-II, aggregate VAMS and BPRS scores. The graphs show predicted mean scores per treatment arm and post-treatment time points, adjusted to sample average baseline values, with 95% CIs.

$p < 0.001$) and BPRS ($t = 2.2$, $df = 43$, 95% CI 0.05 to 11.7, $p = 0.03$). All ECT reductions translated into substantial effects sizes on the standardised scale (BDI-II, 0.9; VAMS, 1.8; BPRS, 0.7). Six-month follow-up data were available for 12 of the 13 ECT remitters and five (42%) of these met the criterion for relapse ($HRSD \geq 12$) whereas two (50%) did so in the rTMS group (Fisher's exact test for comparing proportions: $p = 1$).

Subjective and objective side-effects

Subjective side-effects

Change over time for the CSSES score is shown in *Figure 4* and *Table 2*. The ECT group had a significantly lower subjective side-effect score at end of treatment ($t = 2.45$, $df = 40$, 95% CI 0.51 to 5.33, $p = 0.02$). CSSES scores at baseline were significantly correlated with the HRSD scores (Spearman correlation $r = 0.439$, $p = 0.003$). Change in HRSD score from baseline to end of treatment was also strongly correlated with change in CSSES score (Spearman correlation $r = 0.762$, $p < 0.001$). The self-reported cognitive subscores from the CSSES were analysed separately and results are shown in *Table 2*; there was no significant difference over time or between groups.

Objective side-effects

Table 3 shows results derived from the CAMCOG cognitive examination. No significant differences were found, either between the ECT and rTMS groups or over time, for total CAMCOG and MMSE scores or for subscores on verbal fluency or anterograde and retrograde memory. There was a significant group effect for the attention and orientation subscore ($t = -3.06$, $df = 36$, 95% CI -3.9 to -0.8, $p = 0.004$), with the ECT group showing mild improvement at the end of treatment, in contrast to the rTMS group, where the score had decreased.

Unfortunately, the completion rates for the other neuropsychological tests and for the AMI were too low and insufficient to allow for analysis. A 76-year-old man in the rTMS group died from previously diagnosed prostatic cancer during the 6-month follow-up period. No other major adverse events were recorded, such as seizure induction with rTMS or anaesthetic complications with ECT, and mania was not induced in any patients during the study.

Economic analyses

Table 4 gives the proportion of patients in each of the groups using health and community-based services 6 months after treatment. At 6-month follow-up, service use data were collected on 28 patients (10 in the ECT group and 18 in the rTMS group). A wide range of services were used, delivered by a range of local authority, NHS and voluntary sector organisations. Although moderate use was made of all services, patients made greater contact with NHS services and use of social care services, especially that of the social worker.




FIGURE 4 Mean CSSES scores. The graph shows predicted mean scores per treatment arm and post-treatment time points, adjusted to sample average baseline values, with 95% CIs.

TABLE 2 Subjective symptoms/side-effects as measured by the CSSES

	ECT group ^a (n = 20)			rTMS group ^a (n = 23)			Statistical analysis		
	Baseline	End of treatment	6-month assessment	Baseline	End of treatment	6-month assessment	Group × time interaction	Group effect	Time effect
Symptom/side-effects score	14.2 (4.7)	6.7 (6.4)	7.1 (4.7)	13.2 (5.8)	9.7 (4.6)	8.9 (4.7)	t = -0.70 p = 0.49	t = 2.45 p = 0.02	t = -0.09 p = 0.93
Cognitive subscore	2.4 (1.2)	1.5 (1.4)	1.2 (1.4)	2.1 (1.3)	1.5 (1.2)	2.1 (1.5)	t = 1.43 p = 0.16	t = 1.69 p = 0.10	t = 0.81 p = 0.42

^a Data are mean (SD).

Table 5 summarises the number of hours of carer inputs in the 6-month follow-up period. The table distinguishes personal care, child care, help in and around the home and help outside the home. The total caregiver input was lower after treatment (11 hours per week for ECT patients and 16 hours per week for rTMS patients) than at baseline (19 hours per week for ECT patients and 23 hours per week for rTMS patients).

Patients treated with ECT received a wider range of professional input than those treated with rTMS. A summary of the non-capital resources used during treatment is shown in Table 6. It costs the NHS £211 per administration of ECT; 69% of this cost is related to the professional input and the remainder is related to capital. The cost per session of rTMS was lower than that of ECT. Over the study period, the mean cost of rTMS treatment of £1444 (SD £286) was not significantly higher than the mean cost of ECT at £1314 (SD £525).

The intensity of use of each of the services (Table 5) was weighted by its unit cost to give the total cost of service-based inputs at 6-month follow-up. The costs of all services (both formal and informal) used after treatment are shown in Table 7. NHS, non-NHS and informal care costs were similar between the groups, but informal care costs were higher for the rTMS group (£2795; $p = 0.04$) and contributed substantially to the total cost for this group.

In order to examine the responsiveness of costs to changes in different variables, sensitivity analyses were performed. The effects of the two scenarios on the total mean NHS costs and total costs were assessed (Table 7). The scenarios were (a) varying the unit cost of informal care to the average gross hourly wage for an adult (£11.47) and (b) varying the unit cost of informal care to costs based on the minimum hourly wage (£4.85). Under all scenarios, there were marginal changes in mean total costs.

TABLE 3 CAMCOG assessment and subscores

	ECT group ^a (n = 16)			rTMS group ^a (n = 22)			Statistical analysis		
	Baseline	End of treatment	6-month assessment	Baseline	End of treatment	6-month assessment	Group × time interaction	Group effect	Time effect
CAMCOG (max. = 106)	83.2 (11.1)	87 (14.8)	86.1 (17.3)	85.3 (11.3)	84.7 (17.4)	84.8 (14.5)	t = 0.54 p = 0.62	t = -1.86 p = 0.07	t = 1.10 p = 0.28
MMSE (max. = 30)	24.3 (3.6)	25.6 (3.9)	25.4 (5.3)	25.7 (3.9)	24.4 (5.3)	24.7 (4.8)	t = -0.14 p = 0.89	t = -1.77 p = 0.08	t = 0.75 p = 0.46
Attention and orientation (max. = 17)	12.8 (3.2)	13.9 (3.6)	13.9 (3.5)	14.7 (3.0)	13.5 (3.3)	13.4 (3.8)	t = -0.49 p = 0.63	t = -3.06 p = 0.004	t = 1.15 p = 0.26
Verbal fluency ^b	12.8 (7.1)	14.0 (6.0)	12.6 (8.1)	15.8 (4.1)	16.6 (6.4)	17.0 (5.9)	t = -0.06 p = 0.96	t = -0.01 p = 0.99	t = 0.21 p = 0.83
Anterograde memory (max. = 20)	15.1 (2.9)	16.9 (2.0)	16.5 (1.8)	14.2 (3.6)	15.3 (3.9)	15.1 (3.2)	t = -0.03 p = 0.98	t = -1.22 p = 0.23	t = -0.20 p = 0.84
Retrograde memory (max. = 10)	7.7 (1.9)	7.4 (2.6)	6.9 (2.8)	7.2 (2.3)	6.9 (2.7)	6.6 (2.7)	t = 0.82 p = 0.42	t = -0.76 p = 0.45	t = 0.32 p = 0.75

^a Data are mean (SD).
^b Number of animals named in 1 minute.

TABLE 4 Services used 6 months after treatment: resources used over 3-month period

	ECT group (n = 10)		rTMS group (n = 18)	
	No. using	Mean ^a	No. using	Mean ^a
Hospital-based care				
Inpatient (bed day)	1	25	5	21
Outpatient (attendance) ^b	3	1	7	6
Accident and emergency (attendance)	1	1	2	1
Day hospital (contact)	1	1	- ^d	-
Community-based care				
Day services (day)	1	1	1	1
Lunch club (visit)	1	7	-	-
Social club (visit)	1	25	-	-
District nurse (contact)	1	2	2	4
GP (contact)	5	2	12	6
Practice nurse (contact)	1	1	2	1
Community psychiatrist (contact)	1	1	7	4
Community psychiatric nurse (contact)	2	5	6	11
Social worker (contact)	2	7	3	7
Psychologist (contact)	1	6	3	6
Other community-based professional (contact) ^c	7	2	6	2

^a Mean calculation based on users of relevant service only, not across full sample. The unit of measurement is shown in brackets.
^b Includes outpatient attendances for specialist services (diabetic clinic, X-ray, urine test, psychiatry).
^c Includes dentist, optician and home treatment team.
^d Dashes indicate no use made of service.

TABLE 5 Care giver input by treatment group

	Baseline		6-month follow-up	
	ECT group	rTMS group	ECT group	rTMS group
Child care – number receiving care	–	2	–	2
Child care – hours per week ^a	–	32 (40)	–	17 (16)
Personal care – number receiving care	–	1	2	3
Personal care – hours per week ^a	–	7 (–)	5 (4)	4 (2)
Help in and around home – number receiving care	9	8	1	8
Help in and around home – hours per week ^a	12 (12)	13 (10)	8 (0)	14 (6)
Help outside home – number receiving care	8	7	2	10
Help outside home – hours per week ^a	10 (8)	7 (5)	2 (0)	5 (4)
Total caregiver input (hours per week) ^a	19 (19)	23 (18)	11 (2)	16 (13)

^a Data are shown as mean hours (SD) for those who received help only.

TABLE 6 Non-capital treatment resources for ECT and patients

Resource use	ECT group	rTMS group
Mean time spent in treatment	60 minutes	22 minutes 20 seconds
Mean number of treatment administrations (SD)	(n = 22) 6 (2)	(n = 24) 14 (4)
Professionals:	Average time spent in treatment (minutes)	Average time spent in treatment (minutes)
Consultant psychiatrist	45	25
Anaesthetist	45	NA
Operating departmental assistant	60	NA
Nurse coordinator	60	NA
Ward nurse	60	35 ^a

NA, not applicable.
^a Only applicable to rTMS patients who were inpatients.

TABLE 7 Mean total costs at 6-month follow-up

Cost category	Mean cost (SD) (£)		Mean difference ECT – rTMS	p-Value	95% CI
	ECT group	rTMS group			
Treatment cost ^a	1314 (525)	1444 (286)	–130	0.31	–387 to +127
NHS cost	1245 (2962)	2922 (256)	–1677	0.29	–4866 to +1511
Non-NHS cost	450 (994)	65 (256)	385	0.13	–117 to +888
Total NHS and non-NHS cost	1695 (3002)	2987 (4426)	–1292	0.42	–4527 to +1943
Treatment costs plus 6-month follow-up NHS and non-NHS cost	2834 (3097)	4441 (4477)	–1607	0.28	–4575 to +1316
Informal care	335 (1060)	2795 (3583)	–2460	0.04	–4862 to –57
Total cost including informal care costs	3169 (3261)	7236 (7157)	–4067	0.05	–8136 to +2
Sensitivity analysis: effect on mean total costs under alternative assumptions					
Scenario 1: Informal care cost based on average gross hourly earnings (£11.47)	3133 (3226)	6927 (6819)	–3794	0.06	–7710 to +122
Scenario 2: Informal care cost based on minimum wage (£4.85)	2992 (3105)	5510 (5356)	–2518	0.13	–5806+770

^a Treatment costs are estimated based on a sample of 22 patients in the ECT group and 24 patients in the rTMS group. All other costs are based on sample sizes of 10 and 18 for the ECT and rTMS groups, respectively.




FIGURE 5 CEAC – probability that rTMS is cost-effective as a function of the decision-makers' critical cost-effectiveness ratio




FIGURE 6 CEAC – probability that rTMS is cost-effective as a function of the decision-makers' critical cost-effectiveness ratio

The average length of time spent in at least one category of care giving was 16 hours per week. When the gross hourly wage for an adult was used, as an estimate of the unit cost of care giving, the mean difference in total costs decreased by £273. Under a more conservative estimate of the hourly cost of care giving of £4.85, the difference in the total costs was £1549. However, these differences remained non-significant.

The primary measure of cost-effectiveness was the incremental cost per change in HRSD over the full study period (29 weeks). The secondary analysis was the incremental cost per QALY gained over the same period. It was not necessary (indeed not possible) to calculate ICERs since there were no significant differences in costs and effects on the primary outcome measure. However, there is uncertainty around these results. The development of more sophisticated tools to measure and represent cost-effectiveness has followed criticisms of decision-making purely on the basis of statistical inference. Instead, a Bayesian decision-making approach has been advocated: available data on costs and effects are used to plot a CEAC. The CEAC for rTMS compared with ECT for the primary outcome (HRSD) is shown in *Figure 5*. If society were willing to pay nothing for an improvement in depressive symptoms, there is a 20% probability that rTMS

would be seen as a cost-saving choice compared with ECT. If, however, society is willing to pay £500 for each unit improvement in depressive symptoms for each person (as measured by the HRSD), there is a 99% probability that rTMS would be viewed as cost-effective compared with ECT. By all sensible criteria this would seem a very considerable amount to pay for such a minor change in symptoms.

Patients responded much better to ECT than to rTMS by the end of the allocated treatment course. However, over the 6-month follow-up period ECT patients had a mean QALY gain of 0.0297 (0.056) and rTMS patients had a mean QALY gain of 0.0300 (0.053). The differential QALY gain of treatment with rTMS over ECT was 0.0003 ($p = 0.987$). This suggests that treatment by rTMS does not provide any additional gains in quality of life over ECT over a 6-month period. The lack of a statistically significant difference in QALY gain between the two groups may reflect lack of difference in HRSD scores between groups at 6 months. In terms of cost-effectiveness, at values of willingness to pay up to £30,000 per QALY gained, the probability of cost-effectiveness was 14% (*Figure 6*). Hence, the findings suggest that rTMS has a very low probability of being seen as a cost-effective alternative to ECT for treatment-resistant depression.

Chapter 5

Discussion

The antidepressant effects of ECT and rTMS

This trial showed that ECT is a substantially more effective treatment for severe depression than 3 weeks of rTMS as administered in this study. It would have been ethically unjustifiable to have a placebo group due to the severity of depression in the trial participants. However, it is noteworthy that similar treatment effects were found on all outcome measures. Interestingly, the HRSD scores in the rTMS group improved during the 6-month follow-up period and became similar to those in the ECT group, probably due to ongoing intensive management as reflected in the continuing high costs. Indeed, as previously mentioned, four patients in the rTMS group went on to be treated with ECT.

Rater blinding was clearly not maintained. This was probably due to obvious differences between the treatments and patients inadvertently divulging details. Loss of rater blinding is a potential source of bias, particularly for our primary outcome – the observer-rated HRSD. However, we found similar end-of-treatment results with the self-rated BDI-II and VAMS.

This pragmatic trial attempted to reflect usual medical practice. Patients continued on their usual medications, including benzodiazepines and anti-epileptic mood stabilisers, which could interfere with both ECT and rTMS treatments. Recruitment was slow and the numbers enrolled relatively small, reflecting the difficulties inherent in clinical trials involving patients with severe depression. However, the most common reason for not entering the trial was not consenting to have ECT; such patients were being treated under Section 58 of the Mental Health Act 1983 (see *Figure 1*). As rTMS requires a high degree of cooperation, it would not have been possible to administer it to these patients without their full cooperation. In addition, there was no significant difference between eligible patients who agreed to participate and those who declined with regard to age and sex ratio. Hence the trial reflects the population referred for ECT whom it was possible to treat with rTMS and as such the results are generalisable to this patient population. Loss to

follow-up at 6 months was greater in the ECT group (27% versus 12.5%); the main reason for both groups was unwillingness to participate any more in research.

Previous randomised comparisons of rTMS and ECT have found rTMS to be either less effective than^{61,62} or not statistically significantly different from ECT.^{63,64} These studies are methodologically variable, not powered and most have small sample sizes. In the best designed study, Grunhaus and colleagues⁶⁴ allocated 20 patients to right unilateral ECT [stimulus dosing protocol using 2.5 times the ST; mean number of treatments = 10.3 (3.1); seven patients switched to bilateral ECT when after six treatments their HRSD score did not decrease by $\geq 30\%$] and 20 patients to rTMS (20 daily sessions of 20 trains of 90% of MT at 10 Hz for 6 seconds, i.e. 1200 pulses per day). They found the same remission rate (HRSD ≤ 8) of 30% in both the ECT and rTMS groups. Although the baseline HRSD scores were very similar to those reported in our trial, this remission rate for ECT is nearly half that (59.1%) found in our study, using the same criterion. It is possible that this form of unilateral ECT was less effective, as has been previously reported,²⁵ accounting for the apparent equivalence in treatments. In our trial, five of 12 (42%) ECT remitters met the relapse criterion (HRSD ≥ 12) at 6 months. In previous randomised studies of rTMS and ECT, 20% of responders to ECT (i.e. end-of-treatment HRSD ≤ 10) were deemed to have relapsed (HRSD ≥ 16) after 6 months.⁶⁵ Using these less stringent criteria, the relapse rate for ECT responders ($n = 14$) in our study remains unchanged.

It could be suggested that for rTMS to be as effective as ECT, many more weeks of high-intensity treatment would have been required.¹⁰³ However, it has previously been reported that little further benefit appears to be derived in continuing rTMS in patients with minimal improvement after 2 weeks of rTMS.⁶¹ In our study, five patients decided to stop the rTMS course early due to a perceived lack of benefit. In the remaining 19 patients who received 3 weeks of rTMS, the mean HRSD score declined only 19.7 (32.5)% from baseline. For this trial rTMS stimulus parameters were chosen that were more intensive than

previously published in the hope of achieving greater efficacy. In addition, the mean durations of rTMS and ECT courses were similar, allowing for time-dependent comparison. A recent meta-analysis of trials of real versus placebo rTMS for treating depression concluded that there was currently insufficient evidence to support its routine use but that it did merit further investigation.⁵⁶ We recommend that rTMS parameters (e.g. coil placement, stimulus intensity, number of treatments) be more rigorously characterised before patients are treated with even longer treatment courses.

Side-effects

This is the first report of side-effects in a randomised trial of ECT and rTMS. There is evidence that some of the putative side-effects of ECT are possibly symptoms of depression.^{74,104} Our findings support this. There was a strong correlation between baseline HRSD scores and baseline CSSES symptom scores and also between change in HRSD and CSSES scores. The ECT group, which experienced significantly greater improvement in depressive symptoms, also experienced lower side-effects scores post-treatment than the rTMS group. Interestingly, there was a slight reduction (although not statistically significant) in reported cognitive complaints at end of treatment for both groups, with the two groups having similar CSSES cognitive subscores. This contrasts with a recent non-randomised comparison of rTMS and ECT that found that subjective memory complaints were unchanged from baseline in the ECT group whereas the rTMS group had fewer memory complaints than at baseline.¹⁰⁵ In that study, ECT patients had measurable memory deficits post-treatment whereas the rTMS group did not.

It is well established that depression is often associated with poor memory and concentration.⁸² This is certainly borne out by the baseline scores in the present study, with patients in both groups having evidence of cognitive deficits. Previous studies have shown that ECT can adversely affect cognition. It can interfere with memory, disrupting new learning¹⁰⁶ and causing impairment in remote memory.²⁴ In contrast, studies on rTMS have suggested either no adverse effects on cognitive performance¹⁰⁷ or indeed some positive effects independent of improved mood.¹⁰⁸

Two previous randomised trials comparing rTMS and ECT used the MMSE to assess global cognition

but did not find differences either between the treatment groups or over time.^{61,64} We used a more detailed cognitive assessment instrument but also did not find differences in cognitive performance either between the two treatment groups or over time. We did not detect measurable adverse effects on cognition induced by ECT in the present study. However, neither group's cognitive performance was enhanced as mood improved. The only subtest scores to show a statistically significant difference between the groups was attention and orientation, which improved slightly in the ECT group but not in the rTMS group. The reasons for this are unclear but could reflect enhanced concentration being a sensitive indicator of improved mood. It may be that the CAMCOG interview schedule, originally designed for the diagnosis of dementia, is not a sufficiently sensitive instrument to detect subtle cognitive changes induced by either ECT or rTMS. We attempted additionally to perform more detailed neuropsychological testing, including testing of autobiographical memory, but a high proportion of patients could not complete these tests and we were unable to derive any conclusions from them. However, it is an encouraging finding that ECT did not produce a deterioration in any cognitive measure examined and on some measures there was a trend towards improvement.

None the less, caution is warranted in interpreting these cognitive findings in the light of the high drop-out rate and small sample size. With a larger sample size and a primary focus on cognitive outcome measures, especially retrograde memory, it may be that significant changes in cognition could be demonstrated, including improvements on some cognitive measures as mood improves. Finally, both ECT and rTMS were well tolerated and it is reassuring that no patient dropped out of either treatment because of adverse side-effects.

Economic evaluations

Resources for healthcare are almost always scarce relative to needs or wants, and the purpose of an economic evaluation is to inform the choices that a decision-maker faces in these circumstances. The economic evaluation might even provide an argument for increasing expenditure on services for people with depression in circumstances where the benefits in terms of improved health status and quality of life are substantial. This study included an investigation of the resource implications and cost-effectiveness of rTMS compared with ECT.

The cost of a single session of rTMS was lower than the cost of a session of ECT. Patients receiving rTMS had more treatment sessions, however, and direct treatment costs were not significantly higher. Health and social care service costs were also not significantly different between the groups, but the costs associated with the unpaid inputs of family and other carers were much higher for the rTMS group. Overall, the sum of formal and informal care costs during the 6-month follow-up period were £5782 for the rTMS group (equivalent to £222 per week) and £2030 for the ECT group (or £78 per week). These findings are consistent with previous cost-of-illness research suggesting that depression is associated with high use of health services,¹⁰⁹ and with previous randomised trials of antidepressants that have similarly found high and continuing health services use patterns.¹¹⁰

ECT has been reported to be associated with improved quality of life that is evident within the first month post-treatment and that can be maintained for up to 1 year.^{66,67} In this study, HRQoL was measured using the SF-36, from which it was possible to calculate measures of

QALYs (using the SF-36 approach of Brazier and colleagues).⁹⁵ No relative QALY gains were found for either treatment over the other.

There are now numerous economic evaluations of depression treatment, but very few previous studies of the cost-effectiveness of either ECT or rTMS.¹¹¹ A recent attempt to generate a model proved inconclusive, mainly due to a lack of suitable randomised controlled trial data and uncertainty around the optimal treatment parameters for ECT.⁶⁸ A published decision analytical model of the cost-effectiveness of rTMS suggested that it would be cost-effective compared with ECT alone.⁶⁹ In contrast, this randomised controlled trial has found that rTMS has a low probability of being more cost-effective than ECT. Indeed, when considering the cost of achieving a QALY gain, the cost-effectiveness of rTMS does not look attractive by reference to the threshold revealed by a review and econometric analysis of recommendations made by NICE. This review found an implicit threshold of somewhere between £30,000 and £40,000 per QALY gained, although the figure or range does vary depending on a number of factors.¹¹²

Chapter 6

Conclusions

Implications for the NHS

We have carried out a randomised controlled trial of ECT and rTMS within a defined NHS catchment area population. To our knowledge, this is the first randomised trial involving ECT to be carried out in the UK since the mid-1980s and the first in the UK to report outcomes with contemporary ECT practice using a stimulus dosing protocol. The evidence confirms the clinical effectiveness of ECT for treating major depressive episodes and indicates that 3 weeks of rTMS as administered in this study is not equivalent to ECT. In addition, the evidence suggests that such courses of rTMS would not be cost-effective.

Whether the effectiveness of rTMS as an antidepressant can be improved by identifying optimal treatment parameters remains to be established. The trial results do not support the use of rTMS outside a research setting. However, it is clear that ECT is a powerful antidepressant treatment and what is now required for ECT is to refine the technique further such that side-effects are reduced but its superior effectiveness is maintained.

Recommendations for further research

All the patients randomised to ECT in this study received brief pulse treatment and the majority were given bilateral ECT at $1.5 \times ST$. Brief pulse bilateral ECT appears to be the most commonly

used form of ECT in the UK when compared, for example, with unilateral ECT. However, there is emerging evidence that high-dose unilateral ECT (e.g. at $4-6 \times ST$) may be as effective as standard bilateral ECT but is associated with less cognitive side-effects. It is possible that further reducing the pulse width of the electrical stimulus in ECT may also be associated with less side-effects and it has been suggested that it may be possible to disassociate the therapeutic effects of ECT from its cognitive side-effects. There is therefore a need for large-scale, adequately powered randomised controlled trials comparing different forms of ECT, e.g. bilateral ECT, high-dose unilateral ECT and high-dose ultra-brief pulse unilateral ECT, using simple but sensitive measures for both effectiveness and cognitive side-effects.

The low therapeutic response to the course of rTMS used in this study was disappointing. Although the protocol used was more intensive and prolonged than many previous studies, one possibility was that the treatment protocol was sub-optimal. However, the current evidence base for the effectiveness of rTMS for depression is limited and potentially optimal treatment parameters have not yet been established. Therefore, before any further trials to compare rTMS with established antidepressant treatments, the next generation of randomised trials of rTMS should seek to compare treatment variables such as stimulus intensity, number of stimuli administered and duration of treatment, with a view to quantifying an effect size for antidepressant action.



Acknowledgements

This study was mainly funded by the NHS HTA Programme. It was also supported in part by the Guy's and St Thomas' Charitable Foundation (R001126) and a 2003 Ritter Independent Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD, USA). We wish to thank Lee Wilding, our trial coordinator; Dr Fidel Gallo, Dr Dene Roberston and Ms Jo Creswell for helping with the treatments; and Dr Jennifer Beecham for advice on costing the treatments.

Contribution of authors

All authors listed below were involved in either the conception and design of the study or its analysis and interpretation. All authors were involved in drafting the report and approved the final version. Declan M McLoughlin (Senior Lecturer) conceived and designed the study and is its overall guarantor. Denzil Edwards (Research Psychologist), Michael Philpot (Consultant Psychiatrist), Richard

Brown (Professor of Psychology), Robert Howard (Professor of Old Age Psychiatry), Sabine Landau (Head of Department of Biostatistics and Computing) and Sophia Rabe-Heskith (Reader in Statistics) contributed to the original design, with particular contributions to patient treatment (DE, MP), outcome assessments (RB, RH) and statistical analyses (SL, SR-H). Savitha Eranti (Clinical Research Worker), Andrew Mogg (Clinical Research Worker), Graham Pluck (Research Psychologist) and Richard Purvis (Research Psychologist) contributed to data acquisition, analysis and interpretation plus drafting of the manuscript. Martin Knapp (Professor of Health Economics) and Renée Romeo (Research Worker) undertook the economic analyses and Martin Knapp is the guarantor of the economic aspects of the report. John Rothwell (Professor of Neurophysiology) contributed to the original design with particular contribution to rTMS treatment.



References

1. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders. (DSM-IV)*. Washington, DC: American Psychiatric Association; 1994.
2. World Health Organization. *The World Health Report 2000 – Health Systems: Improving Performance*. Geneva: World Health Organization; 2000.
3. Kind P, Sorensen J. The costs of depression. *Int Clin Psychopharmacol* 1993;**7**:191–5.
4. Keller MB. Depression – a long-term illness. *Br J Psychiatry* 1994;**165**:9–15.
5. Kupfer DJ, Frank E, Perel JM. The advantage of early treatment intervention in recurrent depression. *Arch Gen Psychiatry* 1989;**46**:771–5.
6. Baldwin RC, Simpson S. Treatment resistant depression in the elderly: a review of its conceptualisation, management and relationship to organic brain disease. *J Affect Disord* 1997; **46**:163–73.
7. Souery D, Amsterdam J, de Montigny C, *et al*. Treatment resistant depression: methodological overview and operational criteria. *Eur Neuropsychopharmacol* 1999;**9**:83–91.
8. Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical-response to electroconvulsive-therapy. *Psychiatry Res* 1990;**31**:287–96.
9. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. *Lancet* 2003; **361**:799–808.
10. National Institute for Health and Clinical Excellence. *Guidance on the use of electroconvulsive therapy*. London: NICE; 2003.
11. Calev A, Kochavlev E, Tubi N, *et al*. Change in attitude toward electroconvulsive-therapy – effects of treatment, time since treatment, and severity of depression. *Convulsive Ther* 1991;**7**:184–9.
12. Pettinati HM, Tamburello TA, Ruetsch CR, Kaplan FN. Patient attitudes toward electroconvulsive-therapy. *Psychopharmacol Bull* 1994;**30**:471–5.
13. Walter G, Koster K, Rey JM. Electroconvulsive therapy in adolescents: experience, knowledge, and attitudes of recipients. *J Am Acad Child Adolesc Psychiatry* 1999;**38**:594–9.
14. Walter G, Koster K, Rey JM. Views about treatment among parents of adolescents who received electroconvulsive therapy. *Psychiatric Serv* 1999; **50**:701–2.
15. Veiel HOF. A preliminary profile of neuropsychological deficits associated with major depression. *J Clin Exp Neuropsychol* 1997; **19**:587–603.
16. Elliott R. The neuropsychological profile in unipolar depression. *Trends Cogn Sci* 1998;**2**:447–54.
17. Bench CJ, Friston KJ, Brown RG, Scott LC, Frackowiak RSJ, Dolan RJ. The anatomy of melancholia – focal abnormalities of cerebral blood-flow in major depression. *Psychol Med* 1992; **22**:607–15.
18. Goodwin GM. Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. *J Psychopharmacol* 1997; **11**:115–22.
19. Devanand DP, Fitzsimons L, Prudic J, Sackeim HA. Subjective side effects during electroconvulsive therapy. *Convulsive Ther* 1995;**11**:232–40.
20. Rubin EH, Kinscherf DA, Figiel GS, Zorumski CF. The nature and time course of cognitive side effects during electroconvulsive therapy in the elderly. *J Geriatr Psychiatry Neurol* 1993;**6**:78–83.
21. Stoudemire A, Hill CD, Morris R, Martinosaltzman D, Markwalter H, Lewison B. Cognitive outcome following tricyclic and electroconvulsive treatment of major depression in the elderly. *Am J Psychiatry* 1991;**148**:1336–40.
22. Stoudemire A, Hill CD, Morris R, Dalton ST. Improvement in depression-related cognitive dysfunction following ECT. *J Neuropsychiatry Clin Neurosci* 1995;**7**:31–4.
23. Rose D, Wykes T, Leese M, Bindman J, Fleischmann P. Patients' perspectives on electroconvulsive therapy: systematic review. *BMJ* 2003;**326**:1363–5.
24. Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA. The effects of electroconvulsive therapy on memory of autobiographical and public events. *Arch Gen Psychiatry* 2000;**57**:581–90.
25. Sackeim HA, Prudic J, Devanand DP, *et al*. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. *Arch Gen Psychiatry* 2000;**57**:425–34.

26. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation – applications in neuropsychiatry. *Arch Gen Psychiatry* 1999; **56**:300–11.
27. Reid PD, Shajahan PM, Glabus MF, Ebmeier KP. Transcranial magnetic stimulation in depression. *Br J Psychiatry* 1998; **173**:449–52.
28. Rothwell JC. Techniques and mechanisms of action of transcranial stimulation of the human motor cortex. *J Neurosci Methods* 1997; **74**:113–22.
29. Barker AT, Jalinous R. Non-invasive magnetic stimulation of human motor cortex. *Lancet* 1985; **i**:1106–7.
30. Mills KR. Magnetic brain stimulation: a tool to explore the action of the motor cortex on single human spinal motoneurons. *Trends Neurosci* 1991; **14**:401–5.
31. Chen R, Classen J, Gerloff C, *et al.* Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. *Neurology* 1997; **48**:1398–403.
32. Hallett M. Transcranial magnetic stimulation and the human brain. *Nature* 2000; **406**:147–50.
33. Walsh V, Cowey A. Transcranial magnetic stimulation and cognitive neuroscience. *Nat Rev Neurosci* 2000; **1**:73–9.
34. Nahas Z, Speer A, Lorberbaum J, *et al.* Safety of rTMS: MRI scans before and after 2 weeks of daily left prefrontal rTMS for depression. *Biol Psychiatry* 1998; **43**:316.
35. Gates JR, Dhuna A, Pascual-Leone A. Lack of pathological changes in human temporal lobes after transcranial magnetic stimulation. *Epilepsia* 1992; **33**:504–8.
36. Wassermann EM, Grafman J, Berry C, *et al.* Use and safety of a new repetitive transcranial magnetic stimulator. *Electroencephalogr Clin Neurophysiol* 1996; **101**:412–17.
37. Jahanshahi M, Ridding MC, Limousin P, *et al.* Rapid rate transcranial magnetic stimulation – a safety study. *Electroencephalogr Clin Neurophysiol* 1997; **105**:422–9.
38. Speer AM, Repella JD, Figueras S, *et al.* Lack of adverse cognitive effects of 1 Hz and 20 Hz repetitive transcranial magnetic stimulation at 100% of motor threshold over left prefrontal cortex in depression. *J ECT* 2001; **17**:259–63.
39. Wassermann EM. Side effects of repetitive transcranial magnetic stimulation. *Depress Anxiety* 2000; **12**:124–9.
40. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. *Electroencephalogr Clin Neurophysiol* 1998; **108**:1–16.
41. Keel JC, Smith MJ, Wassermann EM. A safety screening questionnaire for transcranial magnetic stimulation. *Clin Neurophysiol* 2001; **112**:720.
42. Belmaker B, Fitzgerald P, George MS, *et al.* Managing the risks of repetitive transcranial stimulation. *CNS Spectrums* 2003; **8**:489.
43. Hoflich G, Kasper S, Hufnagel A, Ruhrmann S, Moller HJ. Application of transcranial magnetic stimulation in treatment of drug-resistant major depression – a report of two cases. *Hum Psychopharmacol* 1993; **8**:361–5.
44. Kolbinger HM, Hoflich G, Hufnagel A, Moller HJ, Kasper S. Transcranial magnetic stimulation (TMS) in the treatment of major depression: a pilot study. *Hum Psychopharmacol* 1995; **10**:305–10.
45. Grisar N, Yaroslavski U, Abarbanel J, Lamberg T, Belmaker RH. Transcranial magnetic stimulation in depression and schizophrenia. *Eur Neuropsychopharmacol* 1994; **4**:287–8.
46. George MS, Wassermann EM, Williams WA, *et al.* Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. *Neuroreport* 1995; **6**:1853–6.
47. Pascual-Leone A, Rubio B, Pallardo F, Catala MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. *Lancet* 1996; **348**:233–7.
48. George MS, Wassermann EM, Kimbrell TA, *et al.* Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. *Am J Psychiatry* 1997; **154**:1752–6.
49. Figiel GS, Epstein C, McDonald WM, *et al.* The use of rapid-rate transcranial magnetic stimulation (rTMS) in refractory depressed patients. *J Neuropsychiatry Clin Neurosci* 1998; **10**:20–5.
50. Loo C, Mitchell P, Sachdev P, McDarmont B, Parker G, Gandevia S. Double-blind controlled investigation of transcranial magnetic stimulation for the treatment of resistant major depression. *Am J Psychiatry* 1999; **156**:946–8.
51. Klein E, Kreinin I, Christyakov A, *et al.* Therapeutic efficacy of right prefrontal slow repetitive transcranial magnetic stimulation in major depression – a double-blind controlled study. *Arch Gen Psychiatry* 1999; **56**:315–20.
52. McNamara B, Ray JL, Arthurs OJ, Boniface S. Transcranial magnetic stimulation for depression and other psychiatric disorders. *Psychol Med* 2001; **31**:1141–6.
53. Holtzheimer PE, Russo J, Avery DH. A meta-analysis of repetitive transcranial magnetic

- stimulation in the treatment of depression. *Psychopharmacol Bull* 2001;**35**:149–69.
54. Burt T, Lisanby SH, Sackeim HA. Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. *Int J Neuropsychopharmacol* 2002; **5**:73–103.
 55. Kozel FA, George MS. Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. *J Psychiatr Pract* 2002;**8**:270–5.
 56. Martin JLR, Barbanoj MJ, Schlaepfer TE, Thompson E, Perez V, Kulisevsky J. Repetitive transcranial magnetic stimulation for the treatment of depression – systematic review and meta-analysis. *Br J Psychiatry* 2003;**182**:480–91.
 57. Couturier JL. Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. *J Psychiatry Neurosci* 2005;**30**:83–90.
 58. Aarre TF, Dahl AA, Johansen JB, Kjonniksen I, Neckelmann D. Efficacy of repetitive transcranial magnetic stimulation in depression: a review of the evidence. *Nord J Psychiatry* 2005;**57**:227–32.
 59. Loo CK, Taylor JL, Gandevia SC, McDermont BN, Mitchell PB, Sachdev PS. Transcranial magnetic stimulation (TMS) in controlled treatment studies: are some “sham” forms active? *Biol Psychiatry* 2000; **47**:325–31.
 60. Lisanby SH, Gutman D, Luber B, Schroeder C, Sackeim HA. Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. *Biol Psychiatry* 2001;**49**:460–3.
 61. Grunhaus L, Dannon PN, Schreiber S, *et al.* Repetitive transcranial magnetic stimulation is as effective as electroconvulsive therapy in the treatment of nondelusional major depressive disorder. *Biol Psychiatry* 2000;**47**:314–24.
 62. Pridmore S, Bruno R, Turnier-Shea Y, Reid P, Rybak M. Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. *Int J Neuropsychopharmacol* 2000;**3**:129–34.
 63. Janicak PG, Dowd SM, Martis B, *et al.* Repetitive transcranial magnetic stimulation versus electroconvulsive therapy for major depression: preliminary results of a randomized trial. *Biol Psychiatry* 2002;**51**:659–67.
 64. Grunhaus L, Schreiber S, Dolberg OT, Polak D, Dannon PN. A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression. *Biol Psychiatry* 2003;**53**:324–31.
 65. Dannon PN, Dolberg OT, Schreiber S, Grunhaus L. Three and six-month outcome following courses of either ECT or rTMS in a population of severely depressed individuals – preliminary report. *Biol Psychiatry* 2002;**51**:687–90.
 66. McCall WV, Reboussin BA, Cohen W, Lawton P. Electroconvulsive therapy is associated with superior symptomatic and functional change in depressed patients after psychiatric hospitalization. *J Affect Disord* 2001;**63**:17–25.
 67. McCall WV, Dunn A, Rosenquist PB. Quality of life and function after electroconvulsive therapy. *Br J Psychiatry* 2004;**185**:405–9.
 68. Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. *Health Technol Assess* 2005;**9**(9).
 69. Kozel FA, George MS, Simpson KN. Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression. *CNS Spectrums* 2004;**9**:476–82.
 70. Roland M, Torgerson DJ. What are pragmatic trials? *BMJ* 1998;**316**:285.
 71. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured clinical interview for DSM-IV-TR Axis I disorders, research version, non-patient edition. (SCID-I/NP)*. New York: Biometrics Research, New York State Psychiatric Institute; 2001.
 72. Pridmore S, Fernandes JA, Nahas Z, Liberatos C, George MS. Motor threshold in transcranial magnetic stimulation: a comparison of a neurophysiological method and a visualization of movement method. *J ECT* 1998;**14**:25–7.
 73. Royal College of Psychiatrists. *The ECT Handbook: The Second Report of the Royal College of Psychiatrists' Special Committee on ECT. Council Report CR39*. London: Royal College of Psychiatrists; 1995.
 74. Sackeim HA, Prudic J, Devanand DP, *et al.* Effects of stimulus-intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive-therapy. *N Engl J Med* 1993; **328**:839–46.
 75. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960;**23**:56–62.
 76. Beck AT, Steer RA, Brown GK. *Beck depression inventory manual*. 2nd ed. San Antonio, TX: The Psychological Corporation; 1996.
 77. Arruda JE, Stern RA, Legendre SA. Assessment of mood state in patients undergoing electroconvulsive therapy: the utility of Visual Analog Mood Scales developed for cognitively

- impaired patients. *Convulsive Ther* 1996; **12**:207–12.
78. Overall JE, Gorham DR. The brief psychiatric rating scale. *Psychol Rep* 1962; **10**:799–812.
 79. Sackeim HA, Ross FR, Hopkins N, Calev L, Devanand DP. Subjective side effects acutely following ECT: associations with treatment modality and clinical response. *Convulsive Ther* 1987; **3**:100–10.
 80. Roth M, Huppert FA, Tym E, Mountjoy CQ. *CAMDEX: The Cambridge Examination for Mental Disorders of the Elderly*. Cambridge: Cambridge University Press; 1988.
 81. Folstein MF, Folstein SE, McHugh PR. “Mini mental state”: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatric Res* 1975; **12**:189–98.
 82. Brown RG, Scott LC, Bench CJ, Dolan RJ. Cognitive function in depression: its relationship to the presence and severity of intellectual decline. *Psychol Med* 1994; **24**:829–47.
 83. Wechsler D. *The Wechsler Adult Intelligence Test – Revised*. New York: The Psychological Corporation; 1981.
 84. Kopelman M, Wilson B, Baddeley A. *AMI: The Autobiographical Memory Interview*. Bury St Edmunds: Thames Valley Test Company; 1990.
 85. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. *Percept Mot Skills* 1958; **8**:271–6.
 86. Smith A. The Symbol Digit Modalities Test: a neuropsychological test for economic screening of learning and other cerebral disorders. *Learn Disord* 1968; **3**:83–91.
 87. Matthews CG, Kløve H. *Instruction manual for the Adult Neuropsychology Test Battery*. Madison, WI: University of Wisconsin Medical School; 1964.
 88. Prudic J, Haskett RF, Mulsant B, *et al*. Resistance to antidepressant medications and short-term clinical response to ECT. *Am J Psychiatry* 1996; **153**:985–92.
 89. Eranti SV, McLoughlin DM. Electroconvulsive therapy – state of the art. *Br J Psychiatry* 2003; **182**:8–9.
 90. Eranti SV, McLoughlin DM. Changing use of ECT. *Br J Psychiatry* 2003; **183**:73.
 91. Beecham JK, Knapp MRJ. Costing psychiatric interventions. In Thornicroft G, Brewin C, Wing J, editors. *Measuring mental health needs*. London: Gaskell; 1992. pp. 170–90.
 92. Beecham J, Knapp M. Costing psychiatric interventions. In Thornicroft G, editor. *Measuring mental health needs*. 2nd ed. London: Gaskell; 2001. pp. 200–24.
 93. Curtis L, Netten A. *Unit costs of health and social care 2004*. Canterbury: PSSRU, University of Kent; 2004.
 94. Ware JE, Gandek B, Aaronson NK, *et al*. The SF-36 Health Survey: development and use in mental health research and the IQOLA Project. *Int J Ment Health* 1994; **23**:49–73.
 95. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. *J Health Econ* 2002; **21**:271–92.
 96. Van Hout BA, Al MJ, Gordon GS, Ruten FFH. Costs, effects and C/E-ratios alongside a clinical trial. *Health Econ* 1994; **3**:309–19.
 97. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies and frequently asked questions. *Health Econ* 2004; **13**:405–15.
 98. Briggs A. Economic evaluation and clinical trials: size matters – the need for greater power in cost analyses poses an ethical dilemma. *BMJ* 2000; **321**:1362–3.
 99. Sturm R, Unutzer J, Katon W. Effectiveness research and implications for study design: sample size and statistical power. *Gen Hosp Psychiatry* 1999; **21**:274–83.
 100. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). *Lancet* 2002; **360**:711–15.
 101. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. *Stat Med* 2000; **19**:3219–36.
 102. Dunn G, Mirandola M, Amaddeo F, Tansella M. Describing, explaining or predicting mental health care costs: a guide to regression models. *Br J Psychiatry* 2003; **183**:398–404.
 103. Gershon AA, Dannon PN, Grunhaus L. Transcranial magnetic stimulation in the treatment of depression. *Am J Psychiatry* 2003; **160**:835–45.
 104. Brodaty H, Berle D, Hickie I, Mason C. ‘Side effects’ of ECT are mainly depressive phenomena and are independent of age. *J Affect Disord* 2001; **66**:237–45.
 105. Schulze-Rauschenbach SC, Harms U, Schlaepfer TE, Maier W, Falkai P, Wagner M. Distinctive neurocognitive effects of repetitive transcranial magnetic stimulation and electroconvulsive therapy in major depression. *Br J Psychiatry* 2005; **186**:410–16.
 106. Steif BL, Sackeim HA, Portnoy S, Decina P, Malitz S. Effects of depression and ECT on anterograde memory. *Biol Psychiatry* 1986; **21**:921–30.

107. Hausmann A, Pascual-Leone A, Kemmler G, *et al.* No deterioration of cognitive performance in an aggressive unilateral and bilateral antidepressant rTMS add-on trial. *J Clin Psychiatry* 2004;**65**:772–82.
108. Martis B, Alam D, Dowd SM, *et al.* Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. *Clin Neurophysiol* 2003;**114**:1125–32.
109. Thomas CM, Morris S. Cost of depression among adults in England in 2000. *Br J Psychiatry* 2003;**183**:514–19.
110. Romeo R, Patel A, Knapp M, Thomas C. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care. *Int Clin Psychopharmacol* 2004;**19**:125–34.
111. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. *J Affect Disord* 2005;**84**:1–13.
112. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. *Health Econ* 2004;**13**:437–52.



Health Technology Assessment Programme

Director,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Deputy Director,
Professor Jon Nicholl,
Director, Medical Care Research
Unit, University of Sheffield,
School of Health and Related
Research

Prioritisation Strategy Group

Members

Chair,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Professor Bruce Campbell,
Consultant Vascular & General
Surgeon, Royal Devon & Exeter
Hospital

Professor Robin E Ferner,
Consultant Physician and
Director, West Midlands Centre
for Adverse Drug Reactions,
City Hospital NHS Trust,
Birmingham

Dr Edmund Jessop, Medical
Adviser, National Specialist,
Commissioning Advisory Group
(NSCAG), Department of
Health, London

Professor Jon Nicholl, Director,
Medical Care Research Unit,
University of Sheffield,
School of Health and
Related Research

Dr Ron Zimmern, Director,
Public Health Genetics Unit,
Strangeways Research
Laboratories, Cambridge

HTA Commissioning Board

Members

Programme Director,
Professor Tom Walley,
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool

Chair,
Professor Jon Nicholl,
Director, Medical Care Research
Unit, University of Sheffield,
School of Health and Related
Research

Deputy Chair,
Dr Andrew Farmer,
University Lecturer in General
Practice, Department of
Primary Health Care,
University of Oxford

Dr Jeffrey Aronson,
Reader in Clinical
Pharmacology, Department of
Clinical Pharmacology,
Radcliffe Infirmary, Oxford

Professor Deborah Ashby,
Professor of Medical Statistics,
Department of Environmental
and Preventative Medicine,
Queen Mary University of
London

Professor Ann Bowling,
Professor of Health Services
Research, Primary Care and
Population Studies,
University College London

Professor John Cairns,
Professor of Health Economics,
Public Health Policy,
London School of Hygiene
and Tropical Medicine,
London

Professor Nicky Cullum,
Director of Centre for Evidence
Based Nursing, Department of
Health Sciences, University of
York

Professor Jon Deeks,
Professor of Health Statistics,
University of Birmingham

Professor Jenny Donovan,
Professor of Social Medicine,
Department of Social Medicine,
University of Bristol

Professor Freddie Hamdy,
Professor of Urology,
University of Sheffield

Professor Allan House,
Professor of Liaison Psychiatry,
University of Leeds

Professor Sallie Lamb, Director,
Warwick Clinical Trials Unit,
University of Warwick

Professor Stuart Logan,
Director of Health & Social
Care Research, The Peninsula
Medical School, Universities of
Exeter & Plymouth

Professor Miranda Mugford,
Professor of Health Economics,
University of East Anglia

Dr Linda Patterson,
Consultant Physician,
Department of Medicine,
Burnley General Hospital

Professor Ian Roberts,
Professor of Epidemiology &
Public Health, Intervention
Research Unit, London School
of Hygiene and Tropical
Medicine

Professor Mark Sculpher,
Professor of Health Economics,
Centre for Health Economics,
Institute for Research in the
Social Services,
University of York

Professor Kate Thomas,
Professor of Complementary
and Alternative Medicine,
University of Leeds

Professor David John Torgerson,
Director of York Trial Unit,
Department of Health Sciences,
University of York

Professor Hywel Williams,
Professor of
Dermato-Epidemiology,
University of Nottingham

Diagnostic Technologies & Screening Panel

Members

Chair,

Dr Ron Zimmern, Director of the Public Health Genetics Unit, Strangeways Research Laboratories, Cambridge

Ms Norma Armston, Freelance Consumer Advocate, Bolton

Professor Max Bachmann, Professor of Health Care Interfaces, Department of Health Policy and Practice, University of East Anglia

Professor Rudy Bilous, Professor of Clinical Medicine & Consultant Physician, The Academic Centre, South Tees Hospitals NHS Trust

Ms Dea Birkett, Service User Representative, London

Dr Paul Cockcroft, Consultant Medical Microbiologist and Clinical Director of Pathology, Department of Clinical Microbiology, St Mary's Hospital, Portsmouth

Professor Adrian K Dixon, Professor of Radiology, University Department of Radiology, University of Cambridge Clinical School

Dr David Elliman, Consultant in Community Child Health, Islington PCT & Great Ormond Street Hospital, London

Professor Glyn Elwyn, Research Chair, Centre for Health Sciences Research, Cardiff University, Department of General Practice, Cardiff

Professor Paul Glasziou, Director, Centre for Evidence-Based Practice, University of Oxford

Dr Jennifer J Kurinczuk, Consultant Clinical Epidemiologist, National Perinatal Epidemiology Unit, Oxford

Dr Susanne M Ludgate, Clinical Director, Medicines & Healthcare Products Regulatory Agency, London

Mr Stephen Pilling, Director, Centre for Outcomes, Research & Effectiveness, Joint Director, National Collaborating Centre for Mental Health, University College London

Mrs Una Rennard, Service User Representative, Oxford

Dr Phil Shackley, Senior Lecturer in Health Economics, Academic Vascular Unit, University of Sheffield

Dr Margaret Somerville, Director of Public Health Learning, Peninsula Medical School, University of Plymouth

Dr Graham Taylor, Scientific Director & Senior Lecturer, Regional DNA Laboratory, The Leeds Teaching Hospitals

Professor Lindsay Wilson Turnbull, Scientific Director, Centre for MR Investigations & YCR Professor of Radiology, University of Hull

Professor Martin J Whittle, Clinical Co-director, National Co-ordinating Centre for Women's and Childhealth

Dr Dennis Wright, Consultant Biochemist & Clinical Director, The North West London Hospitals NHS Trust, Middlesex

Pharmaceuticals Panel

Members

Chair,

Professor Robin Ferner, Consultant Physician and Director, West Midlands Centre for Adverse Drug Reactions, City Hospital NHS Trust, Birmingham

Ms Anne Baileiff, Consultant Nurse in First Contact Care, Southampton City Primary Care Trust, University of Southampton

Professor Imti Choonara, Professor in Child Health, Academic Division of Child Health, University of Nottingham

Professor John Geddes, Professor of Epidemiological Psychiatry, University of Oxford

Mrs Barbara Greggains, Non-Executive Director, Greggains Management Ltd

Dr Bill Gutteridge, Medical Adviser, National Specialist Commissioning Advisory Group (NSCAG), London

Mrs Sharon Hart, Consultant Pharmaceutical Adviser, Reading

Dr Jonathan Karnon, Senior Research Fellow, Health Economics and Decision Science, University of Sheffield

Dr Yoon Loke, Senior Lecturer in Clinical Pharmacology, University of East Anglia

Ms Barbara Meredith, Lay Member, Epsom

Dr Andrew Prentice, Senior Lecturer and Consultant Obstetrician & Gynaecologist, Department of Obstetrics & Gynaecology, University of Cambridge

Dr Frances Rotblat, CPMP Delegate, Medicines & Healthcare Products Regulatory Agency, London

Dr Martin Shelly, General Practitioner, Leeds

Mrs Katrina Simister, Assistant Director New Medicines, National Prescribing Centre, Liverpool

Dr Richard Tiner, Medical Director, Medical Department, Association of the British Pharmaceutical Industry, London

Therapeutic Procedures Panel

Members

<p>Chair, Professor Bruce Campbell, Consultant Vascular and General Surgeon, Department of Surgery, Royal Devon & Exeter Hospital</p>	<p>Professor Matthew Cooke, Professor of Emergency Medicine, Warwick Emergency Care and Rehabilitation, University of Warwick</p> <p>Mr Mark Emberton, Senior Lecturer in Oncological Urology, Institute of Urology, University College Hospital</p> <p>Professor Paul Gregg, Professor of Orthopaedic Surgical Science, Department of General Practice and Primary Care, South Tees Hospital NHS Trust, Middlesbrough</p> <p>Ms Maryann L Hardy, Lecturer, Division of Radiography, University of Bradford</p>	<p>Dr Simon de Lusignan, Senior Lecturer, Primary Care Informatics, Department of Community Health Sciences, St George's Hospital Medical School, London</p> <p>Dr Peter Martin, Consultant Neurologist, Addenbrooke's Hospital, Cambridge</p> <p>Professor Neil McIntosh, Edward Clark Professor of Child Life & Health, Department of Child Life & Health, University of Edinburgh</p> <p>Professor Jim Neilson, Professor of Obstetrics and Gynaecology, Department of Obstetrics and Gynaecology, University of Liverpool</p>	<p>Dr John C Pounsford, Consultant Physician, Directorate of Medical Services, North Bristol NHS Trust</p> <p>Dr Karen Roberts, Nurse Consultant, Queen Elizabeth Hospital, Gateshead</p> <p>Dr Vimal Sharma, Consultant Psychiatrist/Hon. Senior Lecturer, Mental Health Resource Centre, Cheshire and Wirral Partnership NHS Trust, Wallasey</p> <p>Professor Scott Weich, Professor of Psychiatry, Division of Health in the Community, University of Warwick</p>
<p>Dr Mahmood Adil, Deputy Regional Director of Public Health, Department of Health, Manchester</p> <p>Dr Aileen Clarke, Consultant in Public Health, Public Health Resource Unit, Oxford</p>			

Disease Prevention Panel

Members

<p>Chair, Dr Edmund Jessop, Medical Adviser, National Specialist Commissioning Advisory Group (NSCAG), London</p> <p>Mrs Sheila Clark, Chief Executive, St James's Hospital, Portsmouth</p> <p>Mr Richard Copeland, Lead Pharmacist: Clinical Economy/Interface, Wansbeck General Hospital, Northumberland</p>	<p>Dr Elizabeth Fellow-Smith, Medical Director, West London Mental Health Trust, Middlesex</p> <p>Mr Ian Flack, Director PPI Forum Support, Council of Ethnic Minority Voluntary Sector Organisations, Stratford</p> <p>Dr John Jackson, General Practitioner, Newcastle upon Tyne</p> <p>Mrs Veronica James, Chief Officer, Horsham District Age Concern, Horsham</p> <p>Professor Mike Kelly, Director, Centre for Public Health Excellence, National Institute for Health and Clinical Excellence, London</p>	<p>Professor Yi Mien Koh, Director of Public Health and Medical Director, London NHS (North West London Strategic Health Authority), London</p> <p>Ms Jeanett Martin, Director of Clinical Leadership & Quality, Lewisham PCT, London</p> <p>Dr Chris McCall, General Practitioner, Dorset</p> <p>Dr David Pencheon, Director, Eastern Region Public Health Observatory, Cambridge</p> <p>Dr Ken Stein, Senior Clinical Lecturer in Public Health, Director, Peninsula Technology Assessment Group, University of Exeter, Exeter</p>	<p>Dr Carol Tannahill, Director, Glasgow Centre for Population Health, Glasgow</p> <p>Professor Margaret Thorogood, Professor of Epidemiology, University of Warwick, Coventry</p> <p>Dr Ewan Wilkinson, Consultant in Public Health, Royal Liverpool University Hospital, Liverpool</p>
--	--	--	--

Expert Advisory Network

Members

Professor Douglas Altman,
Professor of Statistics in
Medicine, Centre for Statistics
in Medicine, University of
Oxford

Professor John Bond,
Director, Centre for Health
Services Research, University of
Newcastle upon Tyne, School of
Population & Health Sciences,
Newcastle upon Tyne

Professor Andrew Bradbury,
Professor of Vascular Surgery,
Solihull Hospital, Birmingham

Mr Shaun Brogan,
Chief Executive, Ridgeway
Primary Care Group, Aylesbury

Mrs Stella Burnside OBE,
Chief Executive,
Regulation and Improvement
Authority, Belfast

Ms Tracy Bury,
Project Manager, World
Confederation for Physical
Therapy, London

Professor Iain T Cameron,
Professor of Obstetrics and
Gynaecology and Head of the
School of Medicine,
University of Southampton

Dr Christine Clark,
Medical Writer & Consultant
Pharmacist, Rossendale

Professor Collette Clifford,
Professor of Nursing & Head of
Research, School of Health
Sciences, University of
Birmingham, Edgbaston,
Birmingham

Professor Barry Cookson,
Director, Laboratory of
Healthcare Associated Infection,
Health Protection Agency,
London

Dr Carl Counsell, Clinical
Senior Lecturer in Neurology,
Department of Medicine &
Therapeutics, University of
Aberdeen

Professor Howard Cuckle,
Professor of Reproductive
Epidemiology, Department of
Paediatrics, Obstetrics &
Gynaecology, University of
Leeds

Dr Katherine Darton,
Information Unit, MIND –
The Mental Health Charity,
London

Professor Carol Dezateux,
Professor of Paediatric
Epidemiology, London

Dr Keith Dodd, Consultant
Paediatrician, Derby

Mr John Dunning,
Consultant Cardiothoracic
Surgeon, Cardiothoracic
Surgical Unit, Papworth
Hospital NHS Trust, Cambridge

Mr Jonathan Earnshaw,
Consultant Vascular Surgeon,
Gloucestershire Royal Hospital,
Gloucester

Professor Martin Eccles,
Professor of Clinical
Effectiveness, Centre for Health
Services Research, University of
Newcastle upon Tyne

Professor Pam Enderby,
Professor of Community
Rehabilitation, Institute of
General Practice and Primary
Care, University of Sheffield

Professor Gene Feder, Professor
of Primary Care Research &
Development, Centre for Health
Sciences, Barts & The London
Queen Mary's School of
Medicine & Dentistry, London

Mr Leonard R Fenwick,
Chief Executive, Newcastle
upon Tyne Hospitals NHS Trust

Mrs Gillian Fletcher,
Antenatal Teacher & Tutor and
President, National Childbirth
Trust, Henfield

Professor Jayne Franklyn,
Professor of Medicine,
Department of Medicine,
University of Birmingham,
Queen Elizabeth Hospital,
Edgbaston, Birmingham

Dr Neville Goodman,
Consultant Anaesthetist,
Southmead Hospital, Bristol

Professor Robert E Hawkins,
CRC Professor and Director of
Medical Oncology, Christie CRC
Research Centre, Christie
Hospital NHS Trust, Manchester

Professor Allen Hutchinson,
Director of Public Health &
Deputy Dean of SchARR,
Department of Public Health,
University of Sheffield

Professor Peter Jones, Professor
of Psychiatry, University of
Cambridge, Cambridge

Professor Stan Kaye, Cancer
Research UK Professor of
Medical Oncology, Section of
Medicine, Royal Marsden
Hospital & Institute of Cancer
Research, Surrey

Dr Duncan Keeley,
General Practitioner (Dr Burch
& Ptnrs), The Health Centre,
Thame

Dr Donna Lamping,
Research Degrees Programme
Director & Reader in Psychology,
Health Services Research Unit,
London School of Hygiene and
Tropical Medicine, London

Mr George Levvy,
Chief Executive, Motor
Neurone Disease Association,
Northampton

Professor James Lindesay,
Professor of Psychiatry for the
Elderly, University of Leicester,
Leicester General Hospital

Professor Julian Little,
Professor of Human Genome
Epidemiology, Department of
Epidemiology & Community
Medicine, University of Ottawa

Professor Rajan Madhok,
Consultant in Public Health,
South Manchester Primary
Care Trust, Manchester

Professor Alexander Markham,
Director, Molecular Medicine
Unit, St James's University
Hospital, Leeds

Professor Alistaire McGuire,
Professor of Health Economics,
London School of Economics

Dr Peter Moore,
Freelance Science Writer, Ashtead

Dr Andrew Mortimore, Public
Health Director, Southampton
City Primary Care Trust,
Southampton

Dr Sue Moss, Associate Director,
Cancer Screening Evaluation
Unit, Institute of Cancer
Research, Sutton

Mrs Julietta Patnick,
Director, NHS Cancer Screening
Programmes, Sheffield

Professor Robert Peveler,
Professor of Liaison Psychiatry,
Royal South Hants Hospital,
Southampton

Professor Chris Price,
Visiting Professor in Clinical
Biochemistry, University of
Oxford

Professor William Rosenberg,
Professor of Hepatology and
Consultant Physician, University
of Southampton, Southampton

Professor Peter Sandercock,
Professor of Medical Neurology,
Department of Clinical
Neurosciences, University of
Edinburgh

Dr Susan Schonfield, Consultant
in Public Health, Hillingdon
PCT, Middlesex

Dr Eamonn Sheridan,
Consultant in Clinical Genetics,
Genetics Department,
St James's University Hospital,
Leeds

Professor Sarah Stewart-Brown,
Professor of Public Health,
University of Warwick,
Division of Health in the
Community Warwick Medical
School, LWMS, Coventry

Professor Ala Szczepura,
Professor of Health Service
Research, Centre for Health
Services Studies, University of
Warwick

Dr Ross Taylor,
Senior Lecturer, Department of
General Practice and Primary
Care, University of Aberdeen

Mrs Joan Webster,
Consumer member, HTA –
Expert Advisory Network

Feedback

The HTA Programme and the authors would like to know your views about this report.

The Correspondence Page on the HTA website (<http://www.hta.ac.uk>) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website.

We look forward to hearing from you.